Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 14
2003 8
2004 7
2005 9
2006 15
2007 11
2008 15
2009 14
2010 19
2011 17
2012 17
2013 21
2014 16
2015 23
2016 36
2017 27
2018 27
2019 30
2020 28
2021 33
2022 27
2023 31
2024 27
2025 10

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

435 results

Results by year

Filters applied: . Clear all
Page 1
LSD1+8a is an RNA biomarker of neuroendocrine prostate cancer.
Kumaraswamy A, Mannan R, Swaim OA, Rodansky E, Wang XM, Udager A, Mehra R, Li H, Morrissey C, Corey E, Haffner MC, Nelson PS, Chinnaiyan AM, Yates JA, Alumkal JJ. Kumaraswamy A, et al. Among authors: nelson ps. Neoplasia. 2025 Mar 14;63:101151. doi: 10.1016/j.neo.2025.101151. Online ahead of print. Neoplasia. 2025. PMID: 40088674 Free article.
We previously determined that LSD1+8a transcripts were detected in an aggressive subtype of prostate cancer harboring a neuronal program-neuroendocrine prostate cancer (NEPC)-but not in prostate adenocarcinomas harboring a glandular program. How …
We previously determined that LSD1+8a transcripts were detected in an aggressive subtype of prostate cancer harboring a neuron …
Defined cellular reprogramming of androgen receptor-active prostate cancer to neuroendocrine prostate cancer.
Li S, Song K, Sun H, Tao Y, Huang A, Bhatia V, Hanratty B, Patel RA, Long HW, Morrissey C, Haffner MC, Nelson PS, Graeber TG, Lee JK. Li S, et al. Among authors: nelson ps. bioRxiv [Preprint]. 2025 Mar 7:2025.02.12.637904. doi: 10.1101/2025.02.12.637904. bioRxiv. 2025. PMID: 40027790 Free PMC article. Preprint.
Neuroendocrine prostate cancer (NEPC) arises primarily through neuroendocrine transdifferentiation (NEtD) as an adaptive mechanism of therapeutic resistance. ...These findings provide important, clinically relevant insights into the biological processes driving NEtD …
Neuroendocrine prostate cancer (NEPC) arises primarily through neuroendocrine transdifferentiation (NEtD) as an adaptive mecha …
Association of Prior PARP Inhibitor Exposure with Clinical Outcomes after (177)Lu-PSMA-617 in Men with Castration-resistant Prostate Cancer and Mutations in DNA Homologous Recombination Repair Genes.
Raychaudhuri R, Tuchayi AM, Low SK, Arafa AT, Graham LS, Gulati R, Pritchard CC, Montgomery RB, Haffner MC, Nelson PS, Yu EY, Hawley JE, Cheng HH, Mo G, Chen DL, Antonarakis ES, Kilari D, Hope TA, Iravani A, Schweizer MT. Raychaudhuri R, et al. Among authors: nelson ps. Eur Urol Oncol. 2025 Feb 6:S2588-9311(25)00002-1. doi: 10.1016/j.euo.2025.01.002. Online ahead of print. Eur Urol Oncol. 2025. PMID: 39920014
BACKGROUND AND OBJECTIVE: The prostate-specific membrane antigen (PSMA) radioligand (177)Lu-PSMA-617 (LuPSMA) is approved for treatment of metastatic castration-resistant prostate cancer (mCRPC). ...
BACKGROUND AND OBJECTIVE: The prostate-specific membrane antigen (PSMA) radioligand (177)Lu-PSMA-617 (LuPSMA) is approved for treatme …
Comparative transcriptomics reveals a mixed basal, club, and hillock epithelial cell identity in castration-resistant prostate cancer.
Pitzen SP, Rudenick AN, Qiu Y, Zhang W, Munro SA, McCluskey BM, Forster C, Bergom HE, Ali A, Boytim E, Lafin JT, Linder S, Ismail M, Devlies W, Sessions CJ, Claessens F, Joniau S, Attard G, Zwart W, Nelson PS, Corey E, Wang Y, Lang JM, Beltran H, Strand D, Antonarakis ES, Hwang J, Murugan P, Huang RS, Dehm SM. Pitzen SP, et al. Among authors: nelson ps. Proc Natl Acad Sci U S A. 2025 Feb 11;122(6):e2415308122. doi: 10.1073/pnas.2415308122. Epub 2025 Feb 6. Proc Natl Acad Sci U S A. 2025. PMID: 39913208
Inhibiting the androgen receptor (AR) is effective for treatment of advanced prostate cancers because of their AR-dependent luminal epithelial cell identity. Tumors progress during therapy to castration-resistant prostate cancer (CRPC) by restoring AR signali …
Inhibiting the androgen receptor (AR) is effective for treatment of advanced prostate cancers because of their AR-dependent luminal e …
High-purity CTC RNA sequencing identifies prostate cancer lineage phenotypes prognostic for clinical outcomes.
Sharifi MN, Sperger JM, Taylor AK, Tippins KE, Reese SR, Carreno V, Kaufmann KR, Chang AH, Nunamaker LA, Linebarger C, Mora-Rodriguez L, Schehr JL, Krause HM, Helzer KT, Bootsma ML, Blitzer GC, Floberg JM, Kyriakopoulos CE, Emamekhoo H, Heath EI, Wells M, Tagawa ST, Sjöström M, Choudhury AD, Yu M, Armstrong AJ, Rathkopf DE, Beltran H, Nelson PS, Feng FY, Dehm SM, Kosoff D, Wei XX, McKay RR, Zhao SG, Lang JM. Sharifi MN, et al. Among authors: nelson ps. Cancer Discov. 2025 Feb 6. doi: 10.1158/2159-8290.CD-24-1509. Online ahead of print. Cancer Discov. 2025. PMID: 39912912
The development of treatment resistance remains universal for patients with metastatic prostate cancer, driven by AR alterations and lineage state transitions. Identifying the evolution of lineage transitions in treatment resistance has been limited by the challenge …
The development of treatment resistance remains universal for patients with metastatic prostate cancer, driven by AR alteratio …
NXP800 Activates the Unfolded Protein Response, Altering AR and E2F Function to Impact Castration-Resistant Prostate Cancer Growth.
Welti J, Bogdan D, Figueiredo I, Coleman I, Jiménez Vacas J, Liodaki K, Weigl F, Buroni L, Zeng W, Bernett I, Bertan C, Roumeliotis TI, Bhamra A, Rekowski J, Gurel B, Neeb AJ, Ning J, Li D, Gil VS, Riisnaes R, Miranda S, Crespo M, Ferreira A, Tunariu N, Pasqua E, Chessum N, Cheeseman M, Te Poele R, Powers M, Carreira S, Choudhary J, Clarke P, Banerji U, Swain A, Jones K, Yuan W, Workman P, Nelson PS, de Bono JS, Sharp A. Welti J, et al. Among authors: nelson ps. Clin Cancer Res. 2025 Mar 17;31(6):1109-1126. doi: 10.1158/1078-0432.CCR-24-2386. Clin Cancer Res. 2025. PMID: 39787247 Free PMC article.
PURPOSE: Advanced prostate cancer is invariably fatal, with the androgen receptor (AR) being a major therapeutic target. ...CONCLUSIONS: Overall, NXP800 has antitumor activity against treatment-resistant prostate cancer models, including molecular subt …
PURPOSE: Advanced prostate cancer is invariably fatal, with the androgen receptor (AR) being a major therapeutic target. ...CO …
Deciphering single-cell heterogeneity and cellular ecosystem dynamics during prostate cancer progression.
Zhao F, Zeng J, Chen C, Zhao X, Zhang T, Thomas GV, Sears RC, Alumkal JJ, Moran AE, Mills GB, Nelson PS, Xia Z. Zhao F, et al. Among authors: nelson ps. bioRxiv [Preprint]. 2024 Dec 20:2024.12.18.629070. doi: 10.1101/2024.12.18.629070. bioRxiv. 2024. PMID: 39764047 Free PMC article. Preprint.
Prostate cancer (PC) progresses from benign epithelium through pre-malignant lesions, localized tumors, metastatic dissemination, and castration-resistant stages, with some cases exhibiting phenotype plasticity under therapeutic pressure. However, high-resolution in …
Prostate cancer (PC) progresses from benign epithelium through pre-malignant lesions, localized tumors, metastatic disseminati …
Increased nuclear factor I-mediated chromatin access drives transition to androgen receptor splice variant dependence in prostate cancer.
Poluben L, Nouri M, Liang J, Chen S, Varkaris A, Ersoy-Fazlioglu B, Voznesensky O, Lee II, Qiu X, Cato L, Seo JH, Freedman ML, Sowalsky AG, Lack NA, Corey E, Nelson PS, Brown M, Long HW, Russo JW, Balk SP. Poluben L, et al. Among authors: nelson ps. Cell Rep. 2025 Jan 28;44(1):115089. doi: 10.1016/j.celrep.2024.115089. Epub 2024 Dec 21. Cell Rep. 2025. PMID: 39709604 Free PMC article.
Androgen receptor (AR) splice variants, of which ARv7 is the most common, are increased in castration-resistant prostate cancer, but the extent to which they drive AR activity is unclear. We generated a subline of VCaP cells (VCaP16) that is resistant to the AR inhi …
Androgen receptor (AR) splice variants, of which ARv7 is the most common, are increased in castration-resistant prostate cancer …
Framework for the Pathology Workup of Metastatic Castration-Resistant Prostate Cancer Biopsies.
Haffner MC, Morris MJ, Ding CC, Sayar E, Mehra R, Robinson B, True LD, Gleave M, Lotan TL, Aggarwal R, Huang J, Loda M, Nelson PS, Rubin MA, Beltran H. Haffner MC, et al. Among authors: nelson ps. Clin Cancer Res. 2025 Feb 3;31(3):466-478. doi: 10.1158/1078-0432.CCR-24-2061. Clin Cancer Res. 2025. PMID: 39589343 Review.
Lineage plasticity and histologic transformation from prostate adenocarcinoma to neuroendocrine (NE) prostate cancer (NEPC) occur in up to 15% to 20% of patients with castration-resistant prostate cancer (CRPC) as a mechanism of treatment resist …
Lineage plasticity and histologic transformation from prostate adenocarcinoma to neuroendocrine (NE) prostate cancer (N …
Small-molecule disruption of androgen receptor-dependent chromatin clusters.
Kohrt SE, Novak EJ, Tapadar S, Wu B, Strope J, Asante Y, Kim H, Chang MS, Gurdak D, Khalil A, Rood M, Raftery E, Stavreva D, Nguyen HM, Brown LG, Ramser M, Peer C, Meyers WM, Aboreden N, Chakravortee M, Sallari R, Nelson PS, Kelly KK, Graham TGW, Darzacq X, Figg WD, Oyelere AK, Corey E, Adelaiye-Ogala R, Gryder BE. Kohrt SE, et al. Among authors: nelson ps. Proc Natl Acad Sci U S A. 2024 Nov 26;121(48):e2406239121. doi: 10.1073/pnas.2406239121. Epub 2024 Nov 19. Proc Natl Acad Sci U S A. 2024. PMID: 39560645
Sustained androgen receptor (AR) signaling during relapse is a central driver of metastatic castration-resistant prostate cancer (mCRPC). Current AR antagonists, such as enzalutamide, fail to provide long-term benefit for the mCRPC patients who have dramatic increas …
Sustained androgen receptor (AR) signaling during relapse is a central driver of metastatic castration-resistant prostate cancer …
PET-Based TheraP Eligibility and Outcomes of VISION-Eligible Patients with Metastatic Castration-Resistant Prostate Cancer Who Received (177)Lu-PSMA-617: Importance of (18)F-FDG-Avid Discordant Findings.
Demirci RA, Ghodsi A, Gulati R, Behnia S, Nelson PS, Cheng HH, Yezefski TA, Haffner MC, Hawley JE, Montgomery RB, Yu EY, Schweizer MT, Chen DL, Iravani A. Demirci RA, et al. Among authors: nelson ps. J Nucl Med. 2025 Jan 3;66(1):47-53. doi: 10.2967/jnumed.124.268167. J Nucl Med. 2025. PMID: 39542703
The VISION and TheraP trials introduced different PET-based criteria for patient selection for treatment with (177)Lu-PSMA-617 (LuPSMA). TheraP used a higher prostate-specific membrane antigen (PSMA) uptake threshold than VISION and required (18)F-FDG PET to exclude patien …
The VISION and TheraP trials introduced different PET-based criteria for patient selection for treatment with (177)Lu-PSMA-617 (LuPSMA). The …
SPECT/CT in Early Response Assessment of Patients with Metastatic Castration-Resistant Prostate Cancer Receiving (177)Lu-PSMA-617.
Demirci RA, Gulati R, Hawley JE, Yezefski T, Haffner MC, Cheng HH, Montgomery RB, Schweizer MT, Yu EY, Nelson PS, Chen DL, Iravani A. Demirci RA, et al. Among authors: nelson ps. J Nucl Med. 2024 Dec 3;65(12):1945-1951. doi: 10.2967/jnumed.124.267665. J Nucl Med. 2024. PMID: 39510589
(177)Lu-PSMA-617 (LuPSMA) is a newly established treatment for patients with metastatic castration-resistant prostate cancer (mCRPC), but survival outcomes vary widely, and predictors of treatment responses are needed. ...We evaluated associations between TTVs and t …
(177)Lu-PSMA-617 (LuPSMA) is a newly established treatment for patients with metastatic castration-resistant prostate cancer ( …
FAP and PSMA Expression by Immunohistochemistry and PET Imaging in Castration-Resistant Prostate Cancer: A Translational Pilot Study.
Huang RR, Zuo C, Mona CE, Holzgreve A, Morrissey C, Nelson PS, Brady L, True L, Sisk A, Czernin J, Calais J, Ye H. Huang RR, et al. Among authors: nelson ps. J Nucl Med. 2024 Dec 3;65(12):1952-1958. doi: 10.2967/jnumed.124.268037. J Nucl Med. 2024. PMID: 39477498
Prostate-specific membrane antigen (PSMA) is a theranostic target for metastatic prostate cancer (PCa). ...Fibroblast activation protein (FAP), expressed by carcinoma-associated fibroblasts in various cancer types, including PCa, has the potential to b …
Prostate-specific membrane antigen (PSMA) is a theranostic target for metastatic prostate cancer (PCa). ...Fibroblast a …
BCL2 expression is enriched in advanced prostate cancer with features of lineage plasticity.
Westaby D, Jiménez-Vacas JM, Figueiredo I, Rekowski J, Pettinger C, Gurel B, Lundberg A, Bogdan D, Buroni L, Neeb A, Padilha A, Taylor J, Zeng W, Das S, Hobern E, Riisnaes R, Crespo M, Miranda S, Ferreira A, Hanratty BP, Nava Rodrigues D, Bertan C, Seed G, Fenor de La Maza MLD, Guo C, Carmichael J, Grochot R, Chandran K, Stavridi A, Varkaris A, Stylianou N, Hollier BG, Tunariu N, Balk SP, Carreira S, Yuan W, Nelson PS, Corey E, Haffner M, de Bono J, Sharp A. Westaby D, et al. Among authors: nelson ps. J Clin Invest. 2024 Sep 17;134(18):e179998. doi: 10.1172/JCI179998. J Clin Invest. 2024. PMID: 39286979 Free PMC article.
The widespread use of potent androgen receptor signaling inhibitors (ARSIs) has led to an increasing emergence of AR-independent castration-resistant prostate cancer (CRPC), typically driven by loss of AR expression, lineage plasticity, and transformation to pros …
The widespread use of potent androgen receptor signaling inhibitors (ARSIs) has led to an increasing emergence of AR-independent castration- …
Crosstalk between bone metastatic cancer cells and sensory nerves in bone metastatic progression.
Park SH, Tsuzuki S, Contino KF, Ollodart J, Eber MR, Yu Y, Steele LR, Inaba H, Kamata Y, Kimura T, Coleman I, Nelson PS, Muñoz-Islas E, Jiménez-Andrade JM, Martin TJ, Mackenzie KD, Stratton JR, Hsu FC, Peters CM, Shiozawa Y. Park SH, et al. Among authors: nelson ps. Life Sci Alliance. 2024 Sep 12;7(12):e202302041. doi: 10.26508/lsa.202302041. Print 2024 Dec. Life Sci Alliance. 2024. PMID: 39266299 Free PMC article.
Although the role of peripheral nerves in cancer progression has been appreciated, little is known regarding cancer/sensory nerve crosstalk and its contribution to bone metastasis and associated pain. In this study, we revealed that the cancer/sensory nerve c …
Although the role of peripheral nerves in cancer progression has been appreciated, little is known regarding cancer/sensory ne …
Molecular consequences of acute versus chronic CDK12 loss in prostate carcinoma nominates distinct therapeutic strategies.
Frank S, Persse T, Coleman I, Bankhead A 3rd, Li D, De-Sarkar N, Wilson D, Rudoy D, Vashisth M, Galipeau P, Yang M, Hanratty B, Dumpit R, Morrissey C, Corey E, Montgomery RB, Haffner MC, Pritchard C, Vasioukhin V, Ha G, Nelson PS. Frank S, et al. Among authors: nelson ps. bioRxiv [Preprint]. 2024 Jul 19:2024.07.16.603734. doi: 10.1101/2024.07.16.603734. bioRxiv. 2024. PMID: 39071291 Free PMC article. Preprint.
Genomic loss of the transcriptional kinase CDK12 occurs in ~6% of metastatic castration-resistant prostate cancers (mCRPC) and correlates with poor patient outcomes. Prior studies demonstrate that acute CDK12 loss confers a homologous recombination (HR) deficiency (HRd) ph …
Genomic loss of the transcriptional kinase CDK12 occurs in ~6% of metastatic castration-resistant prostate cancers (mCRPC) and correl …
Single-cell analysis of treatment-resistant prostate cancer: Implications of cell state changes for cell surface antigen-targeted therapies.
Zaidi S, Park J, Chan JM, Roudier MP, Zhao JL, Gopalan A, Wadosky KM, Patel RA, Sayar E, Karthaus WR, Kates DH, Chaudhary O, Xu T, Masilionis I, Mazutis L, Chaligné R, Obradovic A, Linkov I, Barlas A, Jungbluth AA, Rekhtman N, Silber J, Manova-Todorova K, Watson PA, True LD, Morrissey C, Scher HI, Rathkopf DE, Morris MJ, Goodrich DW, Choi J, Nelson PS, Haffner MC, Sawyers CL. Zaidi S, et al. Among authors: nelson ps. Proc Natl Acad Sci U S A. 2024 Jul 9;121(28):e2322203121. doi: 10.1073/pnas.2322203121. Epub 2024 Jul 5. Proc Natl Acad Sci U S A. 2024. PMID: 38968122 Free PMC article.
A notable example of lineage plasticity is the transformation of prostate adenocarcinoma (PRAD) to neuroendocrine prostate cancer (NEPC)-a growing resistance mechanism that results in the loss of responsiveness to androgen blockade and portends dismal patient …
A notable example of lineage plasticity is the transformation of prostate adenocarcinoma (PRAD) to neuroendocrine prostate …
ONECUT2 acts as a lineage plasticity driver in adenocarcinoma as well as neuroendocrine variants of prostate cancer.
Qian C, Yang Q, Rotinen M, Huang R, Kim H, Gallent B, Yan Y, Cadaneanu RM, Zhang B, Kaochar S, Freedland SJ, Posadas EM, Ellis L, Di Vizio D, Morrissey C, Nelson PS, Brady L, Murali R, Campbell MJ, Yang W, Knudsen BS, Mostaghel EA, Ye H, Garraway IP, You S, Freeman MR. Qian C, et al. Among authors: nelson ps. Nucleic Acids Res. 2024 Jul 22;52(13):7740-7760. doi: 10.1093/nar/gkae547. Nucleic Acids Res. 2024. PMID: 38932701 Free PMC article.
Androgen receptor- (AR-) indifference is a mechanism of resistance to hormonal therapy in prostate cancer (PC). Here we demonstrate that ONECUT2 (OC2) activates resistance through multiple drivers associated with adenocarcinoma, stem-like and neuroendocrine (NE) var …
Androgen receptor- (AR-) indifference is a mechanism of resistance to hormonal therapy in prostate cancer (PC). Here we demons …
Docetaxel and Carboplatin for the Treatment of Patients with Metastatic Castration-resistant Prostate Cancer and Biallelic Inactivation of Genes in the Homologous Recombination DNA Repair Pathway: The ABCD Trial.
Raychaudhuri R, DeJong M, Rettig M, Yu EY, Gulati R, Schweizer MT, Nelson PS, Pritchard CC, Montgomery B, Cheng HH. Raychaudhuri R, et al. Among authors: nelson ps. Eur Urol. 2025 Mar;87(3):375-376. doi: 10.1016/j.eururo.2024.05.025. Epub 2024 Jun 18. Eur Urol. 2025. PMID: 38890069 No abstract available.
Proposal for an optimised definition of adverse pathology (unfavourable histology) that predicts metastatic risk in prostatic adenocarcinoma independent of grade group and pathological stage.
Nguyen JK, Harik LR, Klein EA, Li J, Corrigan D, Liu S, Chan E, Hawley S, Auman H, Newcomb LF, Carroll PR, Cooperberg MR, Filson CP, Simko JP, Nelson PS, Tretiakova MS, Troyer D, True LD, Vakar-Lopez F, Weight CJ, Lin DW, Brooks JD, McKenney JK. Nguyen JK, et al. Among authors: nelson ps. Histopathology. 2024 Oct;85(4):598-613. doi: 10.1111/his.15231. Epub 2024 Jun 3. Histopathology. 2024. PMID: 38828674
AIMS: Histological grading of prostate cancer is a powerful prognostic tool, but current criteria for grade assignment are not fully optimised. ...Most importantly, unfavourable histology stratified grade group 2 prostate cancers into those with and without m …
AIMS: Histological grading of prostate cancer is a powerful prognostic tool, but current criteria for grade assignment are not …
Long-Term Outcomes in Patients Using Protocol-Directed Active Surveillance for Prostate Cancer.
Newcomb LF, Schenk JM, Zheng Y, Liu M, Zhu K, Brooks JD, Carroll PR, Dash A, de la Calle CM, Ellis WJ, Filson CP, Gleave ME, Liss MA, Martin F, McKenney JK, Morgan TM, Tretiakova MS, Wagner AA, Nelson PS, Lin DW. Newcomb LF, et al. Among authors: nelson ps. JAMA. 2024 Jun 25;331(24):2084-2093. doi: 10.1001/jama.2024.6695. JAMA. 2024. PMID: 38814624 Free PMC article.
A cohort of 2155 men with favorable-risk prostate cancer and no prior treatment were enrolled at 10 North American centers through August 2022. EXPOSURE: Active surveillance for prostate cancer. MAIN OUTCOMES AND MEASURES: Cumulative incidence of biops …
A cohort of 2155 men with favorable-risk prostate cancer and no prior treatment were enrolled at 10 North American centers thr …
Assessment of TROP2, CEACAM5 and DLL3 in metastatic prostate cancer: Expression landscape and molecular correlates.
Ajkunic A, Sayar E, Roudier MP, Patel RA, Coleman IM, De Sarkar N, Hanratty B, Adil M, Zhao J, Zaidi S, True LD, Sperger JM, Cheng HH, Yu EY, Montgomery RB, Hawley JE, Ha G, Persse T, Galipeau P, Lee JK, Harmon SA, Corey E, Lang JM, Sawyers CL, Morrissey C, Schweizer MT, Gulati R, Nelson PS, Haffner MC. Ajkunic A, et al. Among authors: nelson ps. NPJ Precis Oncol. 2024 May 17;8(1):104. doi: 10.1038/s41698-024-00599-6. NPJ Precis Oncol. 2024. PMID: 38760413 Free PMC article.
In castration-resistant prostate cancer (CRPC), agents targeting prostate-specific membrane antigen (PSMA) have demonstrated clinical activity. ...We show that DLL3 and CEACAM5 exhibit the highest expression in neuroendocrine prostate cancer (NE …
In castration-resistant prostate cancer (CRPC), agents targeting prostate-specific membrane antigen (PSMA) have demonst …
Androgen receptor splice variants drive castration-resistant prostate cancer metastasis by activating distinct transcriptional programs.
Han D, Labaf M, Zhao Y, Owiredu J, Zhang S, Patel K, Venkataramani K, Steinfeld JS, Han W, Li M, Liu M, Wang Z, Besschetnova A, Patalano S, Mulhearn MJ, Macoska JA, Yuan X, Balk SP, Nelson PS, Plymate SR, Gao S, Siegfried KR, Liu R, Stangis MM, Foxa G, Czernik PJ, Williams BO, Zarringhalam K, Li X, Cai C. Han D, et al. Among authors: nelson ps. J Clin Invest. 2024 Apr 30;134(11):e168649. doi: 10.1172/JCI168649. J Clin Invest. 2024. PMID: 38687617 Free PMC article.
One critical mechanism through which prostate cancer (PCa) adapts to treatments targeting androgen receptor (AR) signaling is the emergence of ligand-binding domain-truncated and constitutively active AR splice variants, particularly AR-V7. ...
One critical mechanism through which prostate cancer (PCa) adapts to treatments targeting androgen receptor (AR) signaling is …
Development and Characterisation of a New Patient-Derived Xenograft Model of AR-Negative Metastatic Castration-Resistant Prostate Cancer.
Turnham DJ, Mullen MS, Bullock NP, Gilroy KL, Richards AE, Patel R, Quintela M, Meniel VS, Seaton G, Kynaston H, Clarkson RWE, Phesse TJ, Nelson PS, Haffner MC, Staffurth JN, Pearson HB. Turnham DJ, et al. Among authors: nelson ps. Cells. 2024 Apr 12;13(8):673. doi: 10.3390/cells13080673. Cells. 2024. PMID: 38667288 Free PMC article.
As the treatment landscape for prostate cancer gradually evolves, the frequency of treatment-induced neuroendocrine prostate cancer (NEPC) and double-negative prostate cancer (DNPC) that is deficient for androgen receptor (AR) and neuroen …
As the treatment landscape for prostate cancer gradually evolves, the frequency of treatment-induced neuroendocrine prostat …
Genomic Correlates of Prostate-Specific Membrane Antigen Expression and Response to (177)Lu-PSMA-617: A Retrospective Multicenter Cohort Study.
Raychaudhuri R, Mo G, Tuchayi AM, Graham L, Gulati R, Pritchard CC, Haffner MC, Yezefski T, Hawley JE, Cheng HH, Yu EY, Grivas P, Montgomery RB, Nelson PS, Chen DL, Hope T, Iravani A, Schweizer MT. Raychaudhuri R, et al. Among authors: nelson ps. JCO Precis Oncol. 2024 Apr;8:e2300634. doi: 10.1200/PO.23.00634. JCO Precis Oncol. 2024. PMID: 38662984
PURPOSE: While (177)Lu-PSMA-617 (LuPSMA) is an effective therapy for many patients with metastatic castration-resistant prostate cancer (mCRPC), biomarkers associated with outcomes are not well defined. We hypothesized that prostate cancer mutational p …
PURPOSE: While (177)Lu-PSMA-617 (LuPSMA) is an effective therapy for many patients with metastatic castration-resistant prostate c …
Y Chromosome Loss and Implications for Oncology.
Dirican CD, Nelson PS. Dirican CD, et al. Among authors: nelson ps. Mol Cancer Res. 2024 Jul 2;22(7):603-612. doi: 10.1158/1541-7786.MCR-24-0105. Mol Cancer Res. 2024. PMID: 38647375 Free PMC article. Review.
However, recent work has demonstrated important roles for the Y chromosome and Y-encoded genes in multiple domains of male health, including cancer. It is well established that males experience shorter lifespans than females, and this sex bias on overall mortality is accen …
However, recent work has demonstrated important roles for the Y chromosome and Y-encoded genes in multiple domains of male health, including …
Single Cell Analysis of Treatment-Resistant Prostate Cancer: Implications of Cell State Changes for Cell Surface Antigen Targeted Therapies.
Zaidi S, Park J, Chan JM, Roudier MP, Zhao JL, Gopalan A, Wadosky KM, Patel RA, Sayar E, Karthaus WR, Henry Kates D, Chaudhary O, Xu T, Masilionis I, Mazutis L, Chaligné R, Obradovic A, Linkov I, Barlas A, Jungbluth A, Rekhtman N, Silber J, Manova-Todorova K, Watson PA, True LD, Morrissey CM, Scher HI, Rathkopf D, Morris MJ, Goodrich DW, Choi J, Nelson PS, Haffner MC, Sawyers CL. Zaidi S, et al. Among authors: nelson ps. bioRxiv [Preprint]. 2024 Apr 12:2024.04.09.588340. doi: 10.1101/2024.04.09.588340. bioRxiv. 2024. Update in: Proc Natl Acad Sci U S A. 2024 Jul 9;121(28):e2322203121. doi: 10.1073/pnas.2322203121. PMID: 38645034 Free PMC article. Updated. Preprint.
A notable example of lineage plasticity is the transformation of prostate adenocarcinoma (PRAD) to neuroendocrine prostate cancer (NEPC)--a growing resistance mechanism that results in the loss of responsiveness to androgen blockade and portends dismal patien …
A notable example of lineage plasticity is the transformation of prostate adenocarcinoma (PRAD) to neuroendocrine prostate …
Defining the challenges and opportunities for using patient-derived models in prostate cancer research.
Brennen WN, Le Magnen C, Karkampouna S, Anselmino N, Bock N, Choo N, Clark AK, Coleman IM, Dolgos R, Ferguson AM, Goode DL, Krutihof-de Julio M, Navone NM, Nelson PS, O'Neill E, Porter LH, Ranasinghe W, Sunada T, Williams ED, Butler LM, Corey E, van Weerden WM, Taylor RA, Risbridger GP, Lawrence MG. Brennen WN, et al. Among authors: nelson ps. Prostate. 2024 May;84(7):623-635. doi: 10.1002/pros.24682. Epub 2024 Mar 7. Prostate. 2024. PMID: 38450798 Free article. Review.
BACKGROUND: There are relatively few widely used models of prostate cancer compared to other common malignancies. This impedes translational prostate cancer research because the range of models does not reflect the diversity of disease seen in clinical …
BACKGROUND: There are relatively few widely used models of prostate cancer compared to other common malignancies. This impedes …
Unraveling the Global Proteome and Phosphoproteome of Prostate Cancer Patient-Derived Xenografts.
Sychev ZE, Day A, Bergom HE, Larson G, Ali A, Ludwig M, Boytim E, Coleman I, Corey E, Plymate SR, Nelson PS, Hwang JH, Drake JM. Sychev ZE, et al. Among authors: nelson ps. Mol Cancer Res. 2024 May 2;22(5):452-464. doi: 10.1158/1541-7786.MCR-23-0976. Mol Cancer Res. 2024. PMID: 38345532 Free PMC article.
Resistance to androgen-deprivation therapies leads to metastatic castration-resistant prostate cancer (mCRPC) of adenocarcinoma (AdCa) origin that can transform into emergent aggressive variant prostate cancer (AVPC), which has neuroendocrine (NE)-like …
Resistance to androgen-deprivation therapies leads to metastatic castration-resistant prostate cancer (mCRPC) of adenocarcinom …
Increased chromatin accessibility mediated by nuclear factor I drives transition to androgen receptor splice variant dependence in castration-resistant prostate cancer.
Poluben L, Nouri M, Liang J, Varkaris A, Ersoy-Fazlioglu B, Voznesensky O, Lee II, Qiu X, Cato L, Seo JH, Freedman ML, Sowalsky AG, Lack NA, Corey E, Nelson PS, Brown M, Long HW, Russo JW, Balk SP. Poluben L, et al. Among authors: nelson ps. bioRxiv [Preprint]. 2024 Jun 24:2024.01.10.575110. doi: 10.1101/2024.01.10.575110. bioRxiv. 2024. Update in: Cell Rep. 2025 Jan 28;44(1):115089. doi: 10.1016/j.celrep.2024.115089. PMID: 38260576 Free PMC article. Updated. Preprint.
Androgen receptor (AR) splice variants, of which ARv7 is the most common, are increased in prostate cancer (PC) that develops resistance to androgen signaling inhibitor drugs, but the extent to which these variants drive AR activity, and whether they have novel func …
Androgen receptor (AR) splice variants, of which ARv7 is the most common, are increased in prostate cancer (PC) that develops …
Noninvasive Detection of Neuroendocrine Prostate Cancer through Targeted Cell-free DNA Methylation.
Franceschini GM, Quaini O, Mizuno K, Orlando F, Ciani Y, Ku SY, Sigouros M, Rothmann E, Alonso A, Benelli M, Nardella C, Auh J, Freeman D, Hanratty B, Adil M, Elemento O, Tagawa ST, Feng FY, Caffo O, Buttigliero C, Basso U, Nelson PS, Corey E, Haffner MC, Attard G, Aparicio A, Demichelis F, Beltran H. Franceschini GM, et al. Among authors: nelson ps. Cancer Discov. 2024 Mar 1;14(3):424-445. doi: 10.1158/2159-8290.CD-23-0754. Cancer Discov. 2024. PMID: 38197680 Free PMC article.
Castration-resistant prostate cancer (CRPC) is a heterogeneous disease associated with phenotypic subtypes that drive therapy response and outcome differences. ...These data support the application of targeted DNA methylation for CRPC-NE detection and patient strati …
Castration-resistant prostate cancer (CRPC) is a heterogeneous disease associated with phenotypic subtypes that drive therapy …
ASSESSMENT OF CELL SURFACE TARGETS IN METASTATIC PROSTATE CANCER: EXPRESSION LANDSCAPE AND MOLECULAR CORRELATES.
Ajkunic A, Sayar E, Roudier MP, Patel RA, Coleman IM, De Sarkar N, Hanratty B, Adil M, Zhao J, Zaidi S, True LD, Sperger JM, Cheng HH, Yu EY, Montgomery RB, Hawley JE, Ha G, Lee JK, Harmon SA, Corey E, Lang JM, Sawyers CL, Morrissey C, Schweizer MT, Gulati R, Nelson PS, Haffner MC. Ajkunic A, et al. Among authors: nelson ps. Res Sq [Preprint]. 2023 Dec 19:rs.3.rs-3745991. doi: 10.21203/rs.3.rs-3745991/v1. Res Sq. 2023. Update in: NPJ Precis Oncol. 2024 May 17;8(1):104. doi: 10.1038/s41698-024-00599-6. PMID: 38196594 Free PMC article. Updated. Preprint.
In castration-resistant prostate cancer (CRPC), agents targeting prostate-specific membrane antigen (PSMA) have demonstrated clinical activity. ...We show that DLL3 and CEACAM5 exhibit the highest expression in neuroendocrine prostate cancer (NE …
In castration-resistant prostate cancer (CRPC), agents targeting prostate-specific membrane antigen (PSMA) have demonst …
High expression of Trop2 is associated with aggressive localized prostate cancer and is a candidate urinary biomarker.
Liu S, Hawley SJ, Kunder CA, Hsu EC, Shen M, Westphalen L, Auman H, Newcomb LF, Lin DW, Nelson PS, Feng Z, Tretiakova MS, True LD, Vakar-Lopez F, Carroll PR, Simko J, Gleave ME, Troyer DA, McKenney JK, Brooks JD, Liss MA, Stoyanova T. Liu S, et al. Among authors: nelson ps. Sci Rep. 2024 Jan 4;14(1):486. doi: 10.1038/s41598-023-50215-z. Sci Rep. 2024. PMID: 38177207 Free PMC article.
The development of novel predictive biomarkers will help with risk stratification, and clinical decision-making, leading to a decrease in over or under-treatment of patients with prostate cancer. Here, we report that Trop2 is a prognostic tissue biomarker for clinic …
The development of novel predictive biomarkers will help with risk stratification, and clinical decision-making, leading to a decrease in ov …
Co-occurring BRCA2/SPOP Mutations Predict Exceptional Poly (ADP-ribose) Polymerase Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer.
Orme JJ, Taza F, De Sarkar N, Tewari AK, Arsalan Naqvi S, Riaz IB, Childs DS, Omar N, Adra N, Ashkar R, Cheng HH, Schweizer MT, Sokolova AO, Agarwal N, Barata P, Sartor O, Bastos D, Smaletz O, Berchuck JE, McClure H, Taplin ME, Aggarwal R, Sternberg CN, Vlachostergios PJ, Alva AS, Mehra N, Nelson PS, Hwang J, Dehm SM, Shi Q, Fleischmann Z, Sokol ES, Elliott A, Huang H, Bryce A, Marshall CH, Antonarakis ES. Orme JJ, et al. Among authors: nelson ps. Eur Urol Oncol. 2024 Aug;7(4):877-887. doi: 10.1016/j.euo.2023.11.014. Epub 2023 Dec 9. Eur Urol Oncol. 2024. PMID: 38072760
BACKGROUND AND OBJECTIVE: BRCA2 mutations in metastatic castration-resistant prostate cancer (mCRPC) confer sensitivity to poly (ADP-ribose) polymerase (PARP) inhibitors. ...In a genomic signature analysis, Catalog of Somatic Mutations in Cancer (COSMIC) SBS3 …
BACKGROUND AND OBJECTIVE: BRCA2 mutations in metastatic castration-resistant prostate cancer (mCRPC) confer sensitivity to pol …
Prostate lineage-specific metabolism governs luminal differentiation and response to antiandrogen treatment.
Giafaglione JM, Crowell PD, Delcourt AML, Hashimoto T, Ha SM, Atmakuri A, Nunley NM, Dang RMA, Tian M, Diaz JA, Tika E, Payne MC, Burkhart DL, Li D, Navone NM, Corey E, Nelson PS, Lin NYC, Blanpain C, Ellis L, Boutros PC, Goldstein AS. Giafaglione JM, et al. Among authors: nelson ps. Nat Cell Biol. 2023 Dec;25(12):1821-1832. doi: 10.1038/s41556-023-01274-x. Epub 2023 Dec 4. Nat Cell Biol. 2023. PMID: 38049604 Free PMC article.
Lineage transitions are a central feature of prostate development, tumourigenesis and treatment resistance. While epigenetic changes are well known to drive prostate lineage transitions, it remains unclear how upstream metabolic signalling contributes to the regulat …
Lineage transitions are a central feature of prostate development, tumourigenesis and treatment resistance. While epigenetic changes …
Temporal evolution reveals bifurcated lineages in aggressive neuroendocrine small cell prostate cancer trans-differentiation.
Chen CC, Tran W, Song K, Sugimoto T, Obusan MB, Wang L, Sheu KM, Cheng D, Ta L, Varuzhanyan G, Huang A, Xu R, Zeng Y, Borujerdpur A, Bayley NA, Noguchi M, Mao Z, Morrissey C, Corey E, Nelson PS, Zhao Y, Huang J, Park JW, Witte ON, Graeber TG. Chen CC, et al. Among authors: nelson ps. Cancer Cell. 2023 Dec 11;41(12):2066-2082.e9. doi: 10.1016/j.ccell.2023.10.009. Epub 2023 Nov 22. Cancer Cell. 2023. PMID: 37995683 Free PMC article.
Trans-differentiation from an adenocarcinoma to a small cell neuroendocrine state is associated with therapy resistance in multiple cancer types. To gain insight into the underlying molecular events of the trans-differentiation, we perform a multi-omics time course analysi …
Trans-differentiation from an adenocarcinoma to a small cell neuroendocrine state is associated with therapy resistance in multiple cance …
SND1 binds to ERG and promotes tumor growth in genetic mouse models of prostate cancer.
Liao SY, Rudoy D, Frank SB, Phan LT, Klezovitch O, Kwan J, Coleman I, Haffner MC, Li D, Nelson PS, Emili A, Vasioukhin V. Liao SY, et al. Among authors: nelson ps. Nat Commun. 2023 Nov 16;14(1):7435. doi: 10.1038/s41467-023-43245-8. Nat Commun. 2023. PMID: 37973913 Free PMC article.
Forced nuclear localization of SND1 prominently increases its growth promoting function irrespective of ERG expression. In mice, prostate-specific Snd1 deletion reduces cancer growth and tumor burden in a prostate cancer model (PB-Cre/Pten(flox/flox)/E …
Forced nuclear localization of SND1 prominently increases its growth promoting function irrespective of ERG expression. In mice, prostate …
Determining clinical perspectives and strategies for improving enrollment of minoritized communities in prostate cancer clinical trials.
Brady L, Lee JR, Yu EY, Lin D, Gore JL, Nelson PS, Shiely F, Nyame YA. Brady L, et al. Among authors: nelson ps. Am J Clin Exp Urol. 2023 Oct 15;11(5):385-394. eCollection 2023. Am J Clin Exp Urol. 2023. PMID: 37941652 Free PMC article.
This study sought to assess the knowledge, attitudes, and practices of clinicians around equity and inclusion in prostate cancer clinical trial initiatives in the United States. METHODS: An anonymous, web-based questionnaire was administered via REDCap (Research Ele …
This study sought to assess the knowledge, attitudes, and practices of clinicians around equity and inclusion in prostate cancer …
ONECUT2 Activates Diverse Resistance Drivers of Androgen Receptor-Independent Heterogeneity in Prostate Cancer.
Qian C, Yang Q, Rotinen M, Huang R, Kim H, Gallent B, Yan Y, Cadaneanu RM, Zhang B, Kaochar S, Freedland SJ, Posadas EM, Ellis L, Vizio DD, Morrissey C, Nelson PS, Brady L, Murali R, Campbell MJ, Yang W, Knudsen BS, Mostaghel EA, Ye H, Garraway IP, You S, Freeman MR. Qian C, et al. Among authors: nelson ps. bioRxiv [Preprint]. 2023 Oct 12:2023.09.28.560025. doi: 10.1101/2023.09.28.560025. bioRxiv. 2023. PMID: 37905039 Free PMC article. Preprint.
Androgen receptor- (AR-) indifference is a mechanism of resistance to hormonal therapy in prostate cancer (PC). Here we demonstrate that the HOX/CUT transcription factor ONECUT2 (OC2) activates resistance through multiple drivers associated with adenocarcinoma, stem …
Androgen receptor- (AR-) indifference is a mechanism of resistance to hormonal therapy in prostate cancer (PC). Here we demons …
Characterization of HOXB13 expression patterns in localized and metastatic castration-resistant prostate cancer.
Patel RA, Sayar E, Coleman I, Roudier MP, Hanratty B, Low JY, Jaiswal N, Ajkunic A, Dumpit R, Ercan C, Salama N, O'Brien VP, Isaacs WB, Epstein JI, De Marzo AM, Trock BJ, Luo J, Brennen WN, Tretiakova M, Vakar-Lopez F, True LD, Goodrich DW, Corey E, Morrissey C, Nelson PS, Hurley PJ, Gulati R, Haffner MC. Patel RA, et al. Among authors: nelson ps. J Pathol. 2024 Jan;262(1):105-120. doi: 10.1002/path.6216. Epub 2023 Oct 18. J Pathol. 2024. PMID: 37850574 Free PMC article.
HOXB13 is a key lineage homeobox transcription factor that plays a critical role in the differentiation of the prostate gland. Several studies have suggested that HOXB13 alterations may be involved in prostate cancer development and progression. ...Taken toge …
HOXB13 is a key lineage homeobox transcription factor that plays a critical role in the differentiation of the prostate gland. Severa …
Concurrent Targeting of HDAC and PI3K to Overcome Phenotypic Heterogeneity of Castration-resistant and Neuroendocrine Prostate Cancers.
Zhang A, Lau NA, Wong A, Brown LG, Coleman IM, De Sarkar N, Li D, DeLucia DC, Labrecque MP, Nguyen HM, Conner JL, Dumpit RF, True LD, Lin DW, Corey E, Alumkal JJ, Nelson PS, Morrissey C, Lee JK. Zhang A, et al. Among authors: nelson ps. Cancer Res Commun. 2023 Nov 20;3(11):2358-2374. doi: 10.1158/2767-9764.CRC-23-0250. Cancer Res Commun. 2023. PMID: 37823778 Free PMC article.
Castration-resistant prostate cancer (CRPC) consists of multiple phenotypic subtypes including androgen receptor (AR)-active prostate cancer (ARPC) and neuroendocrine prostate cancer (NEPC). ...Here we show that fimepinostat, a dual HDAC1 …
Castration-resistant prostate cancer (CRPC) consists of multiple phenotypic subtypes including androgen receptor (AR)-active …
Targeting the fibroblast growth factor pathway in molecular subtypes of castration-resistant prostate cancer.
Labrecque MP, Brown LG, Coleman IM, Nguyen HM, Dalrymple S, Brennen WN, Isaacs JT, Li D, Lakely B, DeLucia DC, Lee JK, Schweizer MT, Lin DW, Corey E, Nelson PS, Morrissey C. Labrecque MP, et al. Among authors: nelson ps. Prostate. 2024 Jan;84(1):100-110. doi: 10.1002/pros.24630. Epub 2023 Oct 5. Prostate. 2024. PMID: 37796107 Free PMC article.
BACKGROUND: Androgen receptor (AR) pathway inhibition remains the cornerstone for prostate cancer therapies. However, castration-resistant prostate cancer (CRPC) tumors can resist AR signaling inhibitors through AR amplification and AR splice variants …
BACKGROUND: Androgen receptor (AR) pathway inhibition remains the cornerstone for prostate cancer therapies. However, castrati …
Tumor-derived biomarkers predict efficacy of B7H3 antibody-drug conjugate treatment in metastatic prostate cancer models.
Agarwal S, Fang L, McGowen K, Yin J, Bowman J, Ku AT, Alilin AN, Corey E, Roudier MP, True LD, Dumpit R, Coleman I, Lee JK, Nelson PS, Capaldo BJ, Mariani A, Hoover C, Senatorov IS, Beshiri M, Sowalsky AG, Hurt EM, Kelly K. Agarwal S, et al. Among authors: nelson ps. J Clin Invest. 2023 Nov 15;133(22):e162148. doi: 10.1172/JCI162148. J Clin Invest. 2023. PMID: 37725435 Free PMC article.
Biomarkers to capture patients who might benefit from specific ADCs have not been systematically determined for any cancer. We present a comprehensive therapeutic and biomarker analysis of a B7H3-ADC with pyrrolobenzodiazepine(PBD) payload in 26 treatment-resistant, metast …
Biomarkers to capture patients who might benefit from specific ADCs have not been systematically determined for any cancer. We presen …
Unraveling the Global Proteome and Phosphoproteome of Prostate Cancer Patient-Derived Xenografts.
Sychev ZE, Day A, Bergom HE, Larson G, Ali A, Ludwig M, Boytim E, Coleman I, Corey E, Plymate SR, Nelson PS, Hwang JH, Drake JM. Sychev ZE, et al. Among authors: nelson ps. bioRxiv [Preprint]. 2023 Aug 5:2023.08.02.551697. doi: 10.1101/2023.08.02.551697. bioRxiv. 2023. Update in: Mol Cancer Res. 2024 May 2;22(5):452-464. doi: 10.1158/1541-7786.MCR-23-0976. PMID: 37577653 Free PMC article. Updated. Preprint.
Resistance to androgen deprivation therapies leads to metastatic castration-resistant prostate cancer (mCRPC) of adenocarcinoma (AdCa) origin that can transform to emergent aggressive variant prostate cancer (AVPC) which has neuroendocrine (NE)-like fe …
Resistance to androgen deprivation therapies leads to metastatic castration-resistant prostate cancer (mCRPC) of adenocarcinom …
Third generation quinoline-3-carboxamide transcriptional disrupter of HDAC4, HIF-1alpha, and MEF-2 signaling for metastatic castration-resistant prostate cancer.
Isaacs JT, Dalrymple SL, Antony L, Marc Rosen D, Coleman IM, Nelson PS, Kostova M, Murray IA, Perdew GH, Denmeade SR, Akinboye ES, Brennen WN. Isaacs JT, et al. Among authors: nelson ps. Prostate. 2023 Nov;83(15):1470-1493. doi: 10.1002/pros.24606. Epub 2023 Aug 9. Prostate. 2023. PMID: 37559436 Free PMC article.
In phase 3 clinical testing against metastatic castration-resistant prostate cancer(mCRPC), TasQ (1 mg/day) increased time-to-progression, but not overall survival. ...These included HDAC4 enzymatic assays, qRT-PCR and western blot analyses of gene and protein expre …
In phase 3 clinical testing against metastatic castration-resistant prostate cancer(mCRPC), TasQ (1 mg/day) increased time-to- …
Pharmacological NF-kappaB inhibition decreases cisplatin chemoresistance in muscle-invasive bladder cancer and reduces cisplatin-induced toxicities.
Gil da Costa RM, Levesque C, Bianchi-Frias D, Chatterjee P, Lam HM, Santos C, Coleman IM, Ferreirinha P, Vilanova M, Pinto da Cunha N, Carvalho H, Moreira-Pais A, Faustino-Rocha A, Neto T, Batista da Costa J, Wright JL, Ferreira R, Oliveira PA, Mendes J, Bastos MMSM, Colaço B, Lopes C, Black PC, Sweeney CJ, Nelson PS. Gil da Costa RM, et al. Among authors: nelson ps. Mol Oncol. 2023 Dec;17(12):2709-2727. doi: 10.1002/1878-0261.13504. Epub 2023 Sep 20. Mol Oncol. 2023. PMID: 37533407 Free PMC article.
Most patients with muscle-invasive bladder cancer (MIBC) are not cured with platinum chemotherapy. Up-regulation of nuclear factor kappa light-chain enhancer of activated B cells (NF-kappaB) is a major mechanism underlying chemoresistance, suggesting that its pharmacologic …
Most patients with muscle-invasive bladder cancer (MIBC) are not cured with platinum chemotherapy. Up-regulation of nuclear factor ka …
LSD1 promotes prostate cancer reprogramming by repressing TP53 signaling independently of its demethylase function.
Kumaraswamy A, Duan Z, Flores D, Zhang C, Sehrawat A, Hu YM, Swaim OA, Rodansky E, Storck WK, Kuleape JA, Bedi K, Mannan R, Wang XM, Udager A, Ravikumar V, Bankhead A 3rd, Coleman I, Lee JK, Morrissey C, Nelson PS, Chinnaiyan AM, Rao A, Xia Z, Yates JA, Alumkal JJ. Kumaraswamy A, et al. Among authors: nelson ps. JCI Insight. 2023 Aug 8;8(15):e167440. doi: 10.1172/jci.insight.167440. JCI Insight. 2023. PMID: 37440313 Free PMC article.
Lysine-specific demethylase 1 (LSD1) is a histone demethylase that promotes stemness and cell survival in cancers such as prostate cancer. Most prostate malignancies are adenocarcinomas with luminal differentiation. However, some tumors undergo cellular repro …
Lysine-specific demethylase 1 (LSD1) is a histone demethylase that promotes stemness and cell survival in cancers such as prostate …
Supraphysiological Androgens Promote the Tumor Suppressive Activity of the Androgen Receptor through cMYC Repression and Recruitment of the DREAM Complex.
Nyquist MD, Coleman IM, Lucas JM, Li D, Hanratty B, Meade H, Mostaghel EA, Plymate SR, Corey E, Haffner MC, Nelson PS. Nyquist MD, et al. Among authors: nelson ps. Cancer Res. 2023 Sep 1;83(17):2938-2951. doi: 10.1158/0008-5472.CAN-22-2613. Cancer Res. 2023. PMID: 37352376 Free PMC article.
The androgen receptor (AR) pathway regulates key cell survival programs in prostate epithelium. The AR represents a near-universal driver and therapeutic vulnerability in metastatic prostate cancer, and targeting AR has a remarkable therapeutic index. ...SIGN …
The androgen receptor (AR) pathway regulates key cell survival programs in prostate epithelium. The AR represents a near-universal dr …
Artificial Intelligence-Based PTEN Loss Assessment as an Early Predictor of Prostate Cancer Metastasis After Surgery: A Multicenter Retrospective Study.
Patel P, Harmon S, Iseman R, Ludkowski O, Auman H, Hawley S, Newcomb LF, Lin DW, Nelson PS, Feng Z, Boyer HD, Tretiakova MS, True LD, Vakar-Lopez F, Carroll PR, Cooperberg MR, Chan E, Simko J, Fazli L, Gleave M, Hurtado-Coll A, Thompson IM, Troyer D, McKenney JK, Wei W, Choyke PL, Bratslavsky G, Turkbey B, Siemens DR, Squire J, Peng YP, Brooks JD, Jamaspishvili T. Patel P, et al. Among authors: nelson ps. Mod Pathol. 2023 Oct;36(10):100241. doi: 10.1016/j.modpat.2023.100241. Epub 2023 Jun 19. Mod Pathol. 2023. PMID: 37343766 Free PMC article.
Phosphatase and tensin homolog (PTEN) loss is associated with adverse outcomes in prostate cancer and can be measured via immunohistochemistry. The purpose of the study was to establish the clinical application of an in-house developed artificial intelligence (AI) i …
Phosphatase and tensin homolog (PTEN) loss is associated with adverse outcomes in prostate cancer and can be measured via immu …
A genome-wide CRISPR screen in human prostate cancer cells reveals drivers of macrophage-mediated cell killing and positions AR as a tumor-intrinsic immunomodulator.
Zaalberg A, Minnee E, Mayayo-Peralta I, Schuurman K, Gregoricchio S, van Schaik TA, Hoekman L, Li D, Corey E, Janssen H, Lieftink C, Prekovic S, Altelaar M, Nelson PS, Beijersbergen RL, Zwart W, Bergman A. Zaalberg A, et al. Among authors: nelson ps. bioRxiv [Preprint]. 2023 Jun 7:2023.06.06.543873. doi: 10.1101/2023.06.06.543873. bioRxiv. 2023. PMID: 37333335 Free PMC article. Preprint.
The crosstalk between prostate cancer (PCa) cells and the tumor microenvironment plays a pivotal role in disease progression and metastasis and could provide novel opportunities for patient treatment. ...As hormonal intervention represents the mainstay therapy for t …
The crosstalk between prostate cancer (PCa) cells and the tumor microenvironment plays a pivotal role in disease progression a …
Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell and tumor-localized IL-12 immunotherapy.
Bhatia V, Kamat NV, Pariva TE, Wu LT, Tsao A, Sasaki K, Sun H, Javier G, Nutt S, Coleman I, Hitchcock L, Zhang A, Rudoy D, Gulati R, Patel RA, Roudier MP, True LD, Srivastava S, Morrissey CM, Haffner MC, Nelson PS, Priceman SJ, Ishihara J, Lee JK. Bhatia V, et al. Among authors: nelson ps. Nat Commun. 2023 Apr 11;14(1):2041. doi: 10.1038/s41467-023-37874-2. Nat Commun. 2023. PMID: 37041154 Free PMC article.
Six transmembrane epithelial antigen of the prostate 1 (STEAP1) is a cell surface antigen for therapeutic targeting in prostate cancer. ...STEAP1 CAR T cells demonstrate reactivity in low antigen density, antitumor activity across metastatic prostate …
Six transmembrane epithelial antigen of the prostate 1 (STEAP1) is a cell surface antigen for therapeutic targeting in prostate …
Analysis of evolutionary dynamics and clonal architecture in prostate cancer.
Conway JR, Tewari AK, Camp SY, Han S, Crowdis J, He MX, Nyame YA, AlDubayan SH, Schultz N, Szallasi Z, Pomerantz MM, Freedman ML, Fong L, Nelson PS, Brown M, Salari K, Allen EV. Conway JR, et al. Among authors: nelson ps. bioRxiv [Preprint]. 2023 Mar 25:2023.03.23.533974. doi: 10.1101/2023.03.23.533974. bioRxiv. 2023. PMID: 36993558 Free PMC article. Preprint.
The extent to which clinical and genomic characteristics associate with prostate cancer clonal architecture, tumor evolution, and therapeutic response remains unclear. Here, we reconstructed the clonal architecture and evolutionary trajectories of 845 prostate …
The extent to which clinical and genomic characteristics associate with prostate cancer clonal architecture, tumor evolution, …
Reversible epigenetic alterations mediate PSMA expression heterogeneity in advanced metastatic prostate cancer.
Sayar E, Patel RA, Coleman IM, Roudier MP, Zhang A, Mustafi P, Low JY, Hanratty B, Ang LS, Bhatia V, Adil M, Bakbak H, Quigley DA, Schweizer MT, Hawley JE, Kollath L, True LD, Feng FY, Bander NH, Corey E, Lee JK, Morrissey C, Gulati R, Nelson PS, Haffner MC. Sayar E, et al. Among authors: nelson ps. JCI Insight. 2023 Apr 10;8(7):e162907. doi: 10.1172/jci.insight.162907. JCI Insight. 2023. PMID: 36821396 Free PMC article.
Prostate-specific membrane antigen (PSMA) is an important cell surface target in prostate cancer. There are limited data on the heterogeneity of PSMA tissue expression in metastatic castration-resistant prostate cancer (mCRPC). Furthermore, the …
Prostate-specific membrane antigen (PSMA) is an important cell surface target in prostate cancer. There are limited dat …
Clinical, pathologic, and molecular features of amphicrine prostate cancer.
Graham LS, Haffner MC, Sayar E, Gawne A, Schweizer MT, Pritchard CC, Coleman I, Nelson PS, Yu EY. Graham LS, et al. Among authors: nelson ps. Prostate. 2023 May;83(7):641-648. doi: 10.1002/pros.24497. Epub 2023 Feb 13. Prostate. 2023. PMID: 36779357 Free PMC article.
BACKGROUND: Amphicrine prostate carcinoma (AMPC) is a poorly defined subset of prostate cancer in which cells co-express luminal prostate epithelial and neuroendocrine markers. ...Our study highlights the need to recognize AMPC as a unique molecularly …
BACKGROUND: Amphicrine prostate carcinoma (AMPC) is a poorly defined subset of prostate cancer in which cells co-expres …
A Phase 1/2 Study of Rapamycin and Cisplatin/Gemcitabine for Treatment of Patients With Muscle-Invasive Bladder Cancer.
Makrakis D, Wright JL, Roudier MP, Garcia J, Vakar-Lopez F, Porter MP, Wang Y, Dash A, Lin D, Schade G, Winters B, Zhang X, Nelson P, Mostaghel E, Cheng HH, Schweizer M, Holt SK, Gore JL, Yu EY, Lam HM, Montgomery B. Makrakis D, et al. Among authors: nelson p. Clin Genitourin Cancer. 2023 Apr;21(2):265-272. doi: 10.1016/j.clgc.2022.12.003. Epub 2022 Dec 23. Clin Genitourin Cancer. 2023. PMID: 36710146 Clinical Trial.
INTRODUCTION: Cisplatin-based neoadjuvant chemotherapy (NAC) followed by cystectomy is the standard for muscle-invasive bladder cancer (MIBC), however, NAC confers only a small survival benefit and new strategies are needed to increase its efficacy. ...
INTRODUCTION: Cisplatin-based neoadjuvant chemotherapy (NAC) followed by cystectomy is the standard for muscle-invasive bladder cancer …
Author Correction: A framework for clinical cancer subtyping from nucleosome profiling of cell-free DNA.
Doebley AL, Ko M, Liao H, Cruikshank AE, Santos K, Kikawa C, Hiatt JB, Patton RD, De Sarkar N, Collier KA, Hoge ACH, Chen K, Zimmer A, Weber ZT, Adil M, Reichel JB, Polak P, Adalsteinsson VA, Nelson PS, MacPherson D, Parsons HA, Stover DG, Ha G. Doebley AL, et al. Among authors: nelson ps. Nat Commun. 2023 Jan 25;14(1):403. doi: 10.1038/s41467-023-36187-8. Nat Commun. 2023. PMID: 36697405 Free PMC article. No abstract available.
The future of patient-derived xenografts in prostate cancer research.
Lawrence MG, Taylor RA, Cuffe GB, Ang LS, Clark AK, Goode DL, Porter LH, Le Magnen C, Navone NM, Schalken JA, Wang Y, van Weerden WM, Corey E, Isaacs JT, Nelson PS, Risbridger GP. Lawrence MG, et al. Among authors: nelson ps. Nat Rev Urol. 2023 Jun;20(6):371-384. doi: 10.1038/s41585-022-00706-x. Epub 2023 Jan 17. Nat Rev Urol. 2023. PMID: 36650259 Free PMC article. Review.
Serially transplantable PDXs are used to study tumour biology and test therapeutics, linking the laboratory to the clinic. Although few prostate cancer PDXs are available in large repositories, over 330 prostate cancer PDXs have been established, spann …
Serially transplantable PDXs are used to study tumour biology and test therapeutics, linking the laboratory to the clinic. Although few p …
Internet-Based Germline Genetic Testing for Men With Metastatic Prostate Cancer.
Cheng HH, Sokolova AO, Gulati R, Bowen D, Knerr SA, Klemfuss N, Grivas P, Hsieh A, Lee JK, Schweizer MT, Yezefski T, Zhou A, Yu EY, Nelson PS, Montgomery B. Cheng HH, et al. Among authors: nelson ps. JCO Precis Oncol. 2023 Jan;7:e2200104. doi: 10.1200/PO.22.00104. JCO Precis Oncol. 2023. PMID: 36623239 Free PMC article.
PURPOSE: Germline mutations in DNA repair genes are present in approximately 10% of men with metastatic prostate cancer (mPC), and guidelines recommend genetic germline testing. Notable barriers exist, including access to genetic counseling, insurance coverage, and …
PURPOSE: Germline mutations in DNA repair genes are present in approximately 10% of men with metastatic prostate cancer (mPC), …
Reply by Authors.
Schweizer MT, True L, Gulati R, Zhao Y, Ellis W, Schade G, Montgomery B, Goyal S, Nega K, Hakansson AK, Liu Y, Davicioni E, Pienta K, Nelson PS, Lin D, Wright J. Schweizer MT, et al. Among authors: nelson ps. J Urol. 2023 Feb;209(2):362-363. doi: 10.1097/JU.0000000000003038.02. Epub 2023 Feb 1. J Urol. 2023. PMID: 36621992 No abstract available.
Pathological Effects of Apalutamide in Lower-risk Prostate Cancer: Results From a Phase II Clinical Trial.
Schweizer MT, True L, Gulati R, Zhao Y, Ellis W, Schade G, Montgomery B, Goyal S, Nega K, Hakansson AK, Liu Y, Davicioni E, Pienta K, Nelson PS, Lin D, Wright J. Schweizer MT, et al. Among authors: nelson ps. J Urol. 2023 Feb;209(2):354-363. doi: 10.1097/JU.0000000000003038. Epub 2023 Feb 1. J Urol. 2023. PMID: 36621991 Free PMC article. Clinical Trial.
PURPOSE: Active surveillance is a safe and effective strategy for men with lower-risk prostate cancer who want to avoid local therapy; however, many patients on active surveillance progress to active treatment (eg, prostatectomy or radiation). ...CONCLUSIONS: The ne …
PURPOSE: Active surveillance is a safe and effective strategy for men with lower-risk prostate cancer who want to avoid local …
Bipolar androgen therapy plus olaparib in men with metastatic castration-resistant prostate cancer.
Schweizer MT, Gulati R, Yezefski T, Cheng HH, Mostaghel E, Haffner MC, Patel RA, De Sarkar N, Ha G, Dumpit R, Woo B, Lin A, Panlasigui P, McDonald N, Lai M, Nega K, Hammond J, Grivas P, Hsieh A, Montgomery B, Nelson PS, Yu EY. Schweizer MT, et al. Among authors: nelson ps. Prostate Cancer Prostatic Dis. 2023 Mar;26(1):194-200. doi: 10.1038/s41391-022-00636-0. Epub 2022 Dec 23. Prostate Cancer Prostatic Dis. 2023. PMID: 36564459 Free PMC article.
BACKGROUND: Bipolar androgen therapy (BAT) results in rapid fluctuation of testosterone (T) between near-castrate and supraphysiological levels and has shown promise in metastatic castration-resistant prostate cancer (mCRPC). Its clinical effects may be mediated thr …
BACKGROUND: Bipolar androgen therapy (BAT) results in rapid fluctuation of testosterone (T) between near-castrate and supraphysiological lev …
Defining cellular population dynamics at single-cell resolution during prostate cancer progression.
Germanos AA, Arora S, Zheng Y, Goddard ET, Coleman IM, Ku AT, Wilkinson S, Song H, Brady NJ, Amezquita RA, Zager M, Long A, Yang YC, Bielas JH, Gottardo R, Rickman DS, Huang FW, Ghajar CM, Nelson PS, Sowalsky AG, Setty M, Hsieh AC. Germanos AA, et al. Among authors: nelson ps. Elife. 2022 Dec 13;11:e79076. doi: 10.7554/eLife.79076. Elife. 2022. PMID: 36511483 Free PMC article.
Advanced prostate malignancies are a leading cause of cancer-related deaths in men, in large part due to our incomplete understanding of cellular drivers of disease progression. We investigate prostate cancer cell dynamics at single-cell resolution fro …
Advanced prostate malignancies are a leading cause of cancer-related deaths in men, in large part due to our incomplete unders …
A framework for clinical cancer subtyping from nucleosome profiling of cell-free DNA.
Doebley AL, Ko M, Liao H, Cruikshank AE, Santos K, Kikawa C, Hiatt JB, Patton RD, De Sarkar N, Collier KA, Hoge ACH, Chen K, Zimmer A, Weber ZT, Adil M, Reichel JB, Polak P, Adalsteinsson VA, Nelson PS, MacPherson D, Parsons HA, Stover DG, Ha G. Doebley AL, et al. Among authors: nelson ps. Nat Commun. 2022 Dec 3;13(1):7475. doi: 10.1038/s41467-022-35076-w. Nat Commun. 2022. PMID: 36463275 Free PMC article.
Griffin employs a GC correction procedure tailored to variable cfDNA fragment sizes, which generates a better representation of chromatin accessibility and improves the accuracy of cancer detection and tumor subtype classification. We demonstrate estrogen receptor subtypin …
Griffin employs a GC correction procedure tailored to variable cfDNA fragment sizes, which generates a better representation of chromatin ac …
Endocrine and paracrine characteristics of neuroendocrine prostate cancer.
Arman T, Nelson PS. Arman T, et al. Among authors: nelson ps. Front Endocrinol (Lausanne). 2022 Nov 11;13:1012005. doi: 10.3389/fendo.2022.1012005. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36440195 Free PMC article.
Prostate cancer is a common malignancy affecting men worldwide. While the vast majority of newly diagnosed prostate cancers are categorized as adenocarcinomas, a spectrum of uncommon tumor types occur including those with small cell and neuroendocrine cell fe …
Prostate cancer is a common malignancy affecting men worldwide. While the vast majority of newly diagnosed prostate can …
Nucleosome Patterns in Circulating Tumor DNA Reveal Transcriptional Regulation of Advanced Prostate Cancer Phenotypes.
De Sarkar N, Patton RD, Doebley AL, Hanratty B, Adil M, Kreitzman AJ, Sarthy JF, Ko M, Brahma S, Meers MP, Janssens DH, Ang LS, Coleman IM, Bose A, Dumpit RF, Lucas JM, Nunez TA, Nguyen HM, McClure HM, Pritchard CC, Schweizer MT, Morrissey C, Choudhury AD, Baca SC, Berchuck JE, Freedman ML, Ahmad K, Haffner MC, Montgomery RB, Corey E, Henikoff S, Nelson PS, Ha G. De Sarkar N, et al. Among authors: nelson ps. Cancer Discov. 2023 Mar 1;13(3):632-653. doi: 10.1158/2159-8290.CD-22-0692. Cancer Discov. 2023. PMID: 36399432 Free PMC article.
Advanced prostate cancers comprise distinct phenotypes, but tumor classification remains clinically challenging. ...We sequenced plasma ctDNA whole genomes from patient-derived xenografts representing a spectrum of androgen receptor active (ARPC) and neuroendocrine (NEPC) …
Advanced prostate cancers comprise distinct phenotypes, but tumor classification remains clinically challenging. ...We sequenced plas …
Stromal FOXF2 suppresses prostate cancer progression and metastasis by enhancing antitumor immunity.
Jia D, Zhou Z, Kwon OJ, Zhang L, Wei X, Zhang Y, Yi M, Roudier MP, Regier MC, Dumpit R, Nelson PS, Headley M, True L, Lin DW, Morrissey C, Creighton CJ, Xin L. Jia D, et al. Among authors: nelson ps. Nat Commun. 2022 Nov 11;13(1):6828. doi: 10.1038/s41467-022-34665-z. Nat Commun. 2022. PMID: 36369237 Free PMC article.
Here we show that increasing prostatic stromal Foxf2 suppresses the growth and progression of both syngeneic and autochthonous mouse prostate cancer models in an immunocompetent context. Mechanistically, Foxf2 moderately attenuates the CAF phenotype and trans …
Here we show that increasing prostatic stromal Foxf2 suppresses the growth and progression of both syngeneic and autochthonous mouse …
Comprehensive assessment of anaplastic lymphoma kinase in localized and metastatic prostate cancer reveals targetable alterations.
Patel RA, Coleman I, Roudier MP, Konnick EQ, Hanratty B, Dumpit R, Lucas JM, Ang LS, Low JY, Tretiakova MS, Ha G, Lee JK, True LD, De Marzo AM, Nelson PS, Morrissey C, Pritchard CC, Haffner MC. Patel RA, et al. Among authors: nelson ps. Cancer Res Commun. 2022 May;2(5):277-285. doi: 10.1158/2767-9764.crc-21-0156. Epub 2022 May 2. Cancer Res Commun. 2022. PMID: 36337169 Free PMC article.
An ALK-expressing neuroendocrine prostate cancer model was sensitive to pharmacological ALK inhibition. In summary, we found that ALK overexpression is rare in primary prostate cancer, but more frequent in metastatic prostate cancers with neuroe …
An ALK-expressing neuroendocrine prostate cancer model was sensitive to pharmacological ALK inhibition. In summary, we found t …
RISING STARS: Heterogeneity and the tumor microenvironment in neuroendocrine prostate cancer.
Brady L, Nelson PS. Brady L, et al. Among authors: nelson ps. J Endocrinol. 2022 Dec 22;256(2):e220211. doi: 10.1530/JOE-22-0211. Print 2023 Feb 1. J Endocrinol. 2022. PMID: 36286645 Free PMC article. Review.
Neuroendocrine prostate cancer, generally arising late in the disease trajectory, is a heterogeneous subtype that infers a worse prognosis and limited treatment options for patients. ...In this review, we discuss current efforts to better understand the heterogeneou …
Neuroendocrine prostate cancer, generally arising late in the disease trajectory, is a heterogeneous subtype that infers a wor …
Transcriptional profiling of matched patient biopsies clarifies molecular determinants of enzalutamide-induced lineage plasticity.
Westbrook TC, Guan X, Rodansky E, Flores D, Liu CJ, Udager AM, Patel RA, Haffner MC, Hu YM, Sun D, Beer TM, Foye A, Aggarwal R, Quigley DA, Youngren JF, Ryan CJ, Gleave M, Wang Y, Huang J, Coleman I, Morrissey C, Nelson PS, Evans CP, Lara P, Reiter RE, Witte O, Rettig M, Wong CK, Weinstein AS, Uzunangelov V, Stuart JM, Thomas GV, Feng FY, Small EJ, Yates JA, Xia Z, Alumkal JJ. Westbrook TC, et al. Among authors: nelson ps. Nat Commun. 2022 Sep 15;13(1):5345. doi: 10.1038/s41467-022-32701-6. Nat Commun. 2022. PMID: 36109521 Free PMC article.
The androgen receptor (AR) signaling inhibitor enzalutamide (enza) is one of the principal treatments for metastatic castration-resistant prostate cancer (CRPC). Several emergent enza clinical resistance mechanisms have been described, including lineage plasticity i …
The androgen receptor (AR) signaling inhibitor enzalutamide (enza) is one of the principal treatments for metastatic castration-resistant …
Reformation of the chondroitin sulfate glycocalyx enables progression of AR-independent prostate cancer.
Al-Nakouzi N, Wang CK, Oo HZ, Nelepcu I, Lallous N, Spliid CB, Khazamipour N, Lo J, Truong S, Collins C, Hui D, Esfandnia S, Adomat H, Clausen TM, Gustavsson T, Choudhary S, Dagil R, Corey E, Wang Y, Chauchereau A, Fazli L, Esko JD, Salanti A, Nelson PS, Gleave ME, Daugaard M. Al-Nakouzi N, et al. Among authors: nelson ps. Nat Commun. 2022 Aug 13;13(1):4760. doi: 10.1038/s41467-022-32530-7. Nat Commun. 2022. PMID: 35963852 Free PMC article.
Lineage plasticity of prostate cancer is associated with resistance to androgen receptor (AR) pathway inhibition (ARPI) and supported by a reactive tumor microenvironment. ...Inhibition of the tumor cell CS glycocalyx delays CRPC progression, and impairs growth and …
Lineage plasticity of prostate cancer is associated with resistance to androgen receptor (AR) pathway inhibition (ARPI) and su …
Patterns of structural variation define prostate cancer across disease states.
Zhou M, Ko M, Hoge AC, Luu K, Liu Y, Russell ML, Hannon WW, Zhang Z, Carrot-Zhang J, Beroukhim R, Van Allen EM, Choudhury AD, Nelson PS, Freedman ML, Taplin ME, Meyerson M, Viswanathan SR, Ha G. Zhou M, et al. Among authors: nelson ps. JCI Insight. 2022 Sep 8;7(17):e161370. doi: 10.1172/jci.insight.161370. JCI Insight. 2022. PMID: 35943799 Free PMC article.
The complex genomic landscape of prostate cancer evolves across disease states under therapeutic pressure directed toward inhibiting androgen receptor (AR) signaling. ...Our results comprehensively define patterns of structural variation in prostate cancer …
The complex genomic landscape of prostate cancer evolves across disease states under therapeutic pressure directed toward inhi …
Assessment of Androgen Receptor Splice Variant-7 as a Biomarker of Clinical Response in Castration-Sensitive Prostate Cancer.
Sowalsky AG, Figueiredo I, Lis RT, Coleman I, Gurel B, Bogdan D, Yuan W, Russo JW, Bright JR, Whitlock NC, Trostel SY, Ku AT, Patel RA, True LD, Welti J, Jimenez-Vacas JM, Rodrigues DN, Riisnaes R, Neeb A, Sprenger CT, Swain A, Wilkinson S, Karzai F, Dahut WL, Balk SP, Corey E, Nelson PS, Haffner MC, Plymate SR, de Bono JS, Sharp A. Sowalsky AG, et al. Among authors: nelson ps. Clin Cancer Res. 2022 Aug 15;28(16):3509-3525. doi: 10.1158/1078-0432.CCR-22-0851. Clin Cancer Res. 2022. PMID: 35695870 Free PMC article.
PURPOSE: Therapies targeting the androgen receptor (AR) have improved the outcome for patients with castration-sensitive prostate cancer (CSPC). Expression of the constitutively active AR splice variant-7 (AR-V7) has shown clinical utility as a predictive biomarker …
PURPOSE: Therapies targeting the androgen receptor (AR) have improved the outcome for patients with castration-sensitive prostate …
Response to supraphysiological testosterone is predicted by a distinct androgen receptor cistrome.
Qiu X, Brown LG, Conner JL, Nguyen HM, Boufaied N, Abou Alaiwi S, Seo JH, El Zarif T, Bell C, O'Connor E, Hanratty B, Pomerantz M, Freedman ML, Brown M, Haffner MC, Nelson PS, Feng FY, Labbé DP, Long HW, Corey E. Qiu X, et al. Among authors: nelson ps. JCI Insight. 2022 May 23;7(10):e157164. doi: 10.1172/jci.insight.157164. JCI Insight. 2022. PMID: 35603787 Free PMC article.
The androgen receptor (AR) is a master transcription factor that regulates prostate cancer (PC) development and progression. Inhibition of AR signaling by androgen deprivation is the first-line therapy with initial efficacy for advanced and recurrent PC. ...
The androgen receptor (AR) is a master transcription factor that regulates prostate cancer (PC) development and progression. I …
Therapeutic Implications for Intrinsic Phenotype Classification of Metastatic Castration-Resistant Prostate Cancer.
Coleman IM, DeSarkar N, Morrissey C, Xin L, Roudier MP, Sayar E, Li D, Corey E, Haffner MC, Nelson PS. Coleman IM, et al. Among authors: nelson ps. Clin Cancer Res. 2022 Jul 15;28(14):3127-3140. doi: 10.1158/1078-0432.CCR-21-4289. Clin Cancer Res. 2022. PMID: 35552660 Free PMC article.
PURPOSE: To determine whether metastatic castration-resistant prostate cancers (mCRPC) partition into molecular phenotypes corresponding to intrinsic differentiation states and ascertain whether these subtypes exhibit specific druggable features and associate with treatmen …
PURPOSE: To determine whether metastatic castration-resistant prostate cancers (mCRPC) partition into molecular phenotypes correspond …
Germline mutations in penetrant cancer predisposition genes are rare in men with prostate cancer selecting active surveillance.
Brady L, Newcomb LF, Zhu K, Zheng Y, Boyer H, Sarkar N, McKenney JK, Brooks JD, Carroll PR, Dash A, Ellis WJ, Filson CP, Gleave ME, Liss MA, Martin F, Morgan TM, Thompson IM, Wagner AA, Pritchard CC, Lin DW, Nelson PS. Brady L, et al. Among authors: nelson ps. Cancer Med. 2022 Nov;11(22):4332-4340. doi: 10.1002/cam4.4778. Epub 2022 Apr 25. Cancer Med. 2022. PMID: 35467778 Free PMC article.
BACKGROUND: Pathogenic germline mutations in several rare penetrant cancer predisposition genes are associated with an increased risk of aggressive prostate cancer (PC). ...METHODS: Men prospectively enrolled in the Canary Prostate Active Surveillance …
BACKGROUND: Pathogenic germline mutations in several rare penetrant cancer predisposition genes are associated with an increased risk …
Comparative genomics of primary prostate cancer and paired metastases: insights from 12 molecular case studies.
Cyrta J, Prandi D, Arora A, Hovelson DH, Sboner A, Rodriguez A, Fedrizzi T, Beltran H, Robinson DR, Gopalan A, True L, Nelson PS, Robinson BD, Mosquera JM, Tomlins SA, Shen R, Demichelis F, Rubin MA. Cyrta J, et al. Among authors: nelson ps. J Pathol. 2022 Jul;257(3):274-284. doi: 10.1002/path.5887. Epub 2022 Mar 28. J Pathol. 2022. PMID: 35220606 Free PMC article.
Primary prostate cancer (PCa) can show marked molecular heterogeneity. However, systematic analyses comparing primary PCa and matched metastases in individual patients are lacking. ...In this pilot study, we collected 12 radical prostatectomy (RP) specimens from men …
Primary prostate cancer (PCa) can show marked molecular heterogeneity. However, systematic analyses comparing primary PCa and …
Understanding Drug Sensitivity and Tackling Resistance in Cancer.
Tyner JW, Haderk F, Kumaraswamy A, Baughn LB, Van Ness B, Liu S, Marathe H, Alumkal JJ, Bivona TG, Chan KS, Druker BJ, Hutson AD, Nelson PS, Sawyers CL, Willey CD. Tyner JW, et al. Among authors: nelson ps. Cancer Res. 2022 Apr 15;82(8):1448-1460. doi: 10.1158/0008-5472.CAN-21-3695. Cancer Res. 2022. PMID: 35195258 Free PMC article.
Decades of research into the molecular mechanisms of cancer and the development of novel therapeutics have yielded a number of remarkable successes. ...This is in part due to the well-documented heterogeneity of cancer, including the diversity of tumor cell lineages …
Decades of research into the molecular mechanisms of cancer and the development of novel therapeutics have yielded a number of remark …
Development and validation of a quantitative reactive stroma biomarker (qRS) for prostate cancer prognosis.
Ruder S, Gao Y, Ding Y, Bu P, Miles B, De Marzo A, Wheeler T, McKenney JK, Auman H, Fazli L, Simko J, Hurtado-Coll A, Troyer DA, Carroll PR, Gleave M, Platz E, Trock B, Han M, Sayeeduddin M, True LD, Rowley D, Lin DW, Nelson PS, Thompson IM, Feng Z, Wei W, Brooks JD, Ittmann M, Lee M, Ayala G. Ruder S, et al. Among authors: nelson ps. Hum Pathol. 2022 Apr;122:84-91. doi: 10.1016/j.humpath.2022.01.009. Epub 2022 Feb 15. Hum Pathol. 2022. PMID: 35176252 Free PMC article.
To develop and validate a new tissue-based biomarker that improves prediction of outcomes in localized prostate cancer by quantifying the host response to tumor. We use digital image analysis and machine learning to develop a biomarker of the prostate stroma …
To develop and validate a new tissue-based biomarker that improves prediction of outcomes in localized prostate cancer by quan …
Analysis of separate training and validation radical prostatectomy cohorts identifies 0.25 mm diameter as an optimal definition for "large" cribriform prostatic adenocarcinoma.
Chan E, McKenney JK, Hawley S, Corrigan D, Auman H, Newcomb LF, Boyer HD, Carroll PR, Cooperberg MR, Klein E, Fazli L, Gleave ME, Hurtado-Coll A, Simko JP, Nelson PS, Thompson IM, Tretiakova MS, Troyer D, True LD, Vakar-Lopez F, Lin DW, Brooks JD, Feng Z, Nguyen JK. Chan E, et al. Among authors: nelson ps. Mod Pathol. 2022 Aug;35(8):1092-1100. doi: 10.1038/s41379-022-01009-7. Epub 2022 Feb 10. Mod Pathol. 2022. PMID: 35145197 Free PMC article.
Cribriform growth pattern is well-established as an adverse pathologic feature in prostate cancer. The literature suggests "large" cribriform glands associate with aggressive behavior; however, published studies use varying definitions for "large". ...
Cribriform growth pattern is well-established as an adverse pathologic feature in prostate cancer. The literature suggests "la …
Paracrine Wnt signaling is necessary for prostate epithelial proliferation.
Wei X, Roudier MP, Kwon OJ, Lee JD, Kong K, Dumpit R, True L, Morrissey C, Lin DW, Nelson PS, Xin L. Wei X, et al. Among authors: nelson ps. Prostate. 2022 Apr;82(5):517-530. doi: 10.1002/pros.24298. Epub 2022 Jan 11. Prostate. 2022. PMID: 35014711 Free PMC article.
INTRODUCTION: The Wnt proteins play key roles in the development, homeostasis, and disease progression of many organs including the prostate. However, the spatiotemporal expression patterns of Wnt proteins in prostate cell lineages at different developmental stages …
INTRODUCTION: The Wnt proteins play key roles in the development, homeostasis, and disease progression of many organs including the prost …
Genomic attributes of homology-directed DNA repair deficiency in metastatic prostate cancer.
De Sarkar N, Dasgupta S, Chatterjee P, Coleman I, Ha G, Ang LS, Kohlbrenner EA, Frank SB, Nunez TA, Salipante SJ, Corey E, Morrissey C, Van Allen E, Schweizer MT, Haffner MC, Patel R, Hanratty B, Lucas JM, Dumpit RF, Pritchard CC, Montgomery RB, Nelson PS. De Sarkar N, et al. Among authors: nelson ps. JCI Insight. 2021 Dec 8;6(23):e152789. doi: 10.1172/jci.insight.152789. JCI Insight. 2021. PMID: 34877933 Free PMC article.
Here, we evaluated whole-exome sequences from 418 metastatic prostate cancers (mPCs) and determined that one-fifth exhibited genomic characteristics of HRRd that included Catalogue Of Somatic Mutations In Cancer mutation signature 3. ...
Here, we evaluated whole-exome sequences from 418 metastatic prostate cancers (mPCs) and determined that one-fifth exhibited genomic …
Inherited TP53 Variants and Risk of Prostate Cancer.
Maxwell KN, Cheng HH, Powers J, Gulati R, Ledet EM, Morrison C, Le A, Hausler R, Stopfer J, Hyman S, Kohlmann W, Naumer A, Vagher J, Greenberg SE, Naylor L, Laurino M, Konnick EQ, Shirts BH, AlDubayan SH, Van Allen EM, Nguyen B, Vijai J, Abida W, Carlo MI, Dubard-Gault M, Lee DJ, Maese LD, Mandelker D, Montgomery B, Morris MJ, Nicolosi P, Nussbaum RL, Schwartz LE, Stadler Z, Garber JE, Offit K, Schiffman JD, Nelson PS, Sartor O, Walsh MF, Pritchard CC. Maxwell KN, et al. Among authors: nelson ps. Eur Urol. 2022 Mar;81(3):243-250. doi: 10.1016/j.eururo.2021.10.036. Epub 2021 Dec 1. Eur Urol. 2022. PMID: 34863587 Free PMC article.
However, there is no known association of prostate cancer with gTP53. OBJECTIVE: To determine whether gTP53 predisposes to prostate cancer. ...CONCLUSIONS: Complementary analyses of prostate cancer incidence in LFS males and gTP53 prevale …
However, there is no known association of prostate cancer with gTP53. OBJECTIVE: To determine whether gTP53 predisposes to …
Evaluating the Outcomes of Active Surveillance in Grade Group 2 Prostate Cancer: Prospective Results from the Canary PASS Cohort.
Waisman Malaret AJ, Chang P, Zhu K, Zheng Y, Newcomb LF, Liu M, McKenney JK, Brooks JD, Carroll P, Dash A, Filson CP, Gleave ME, Liss M, Martin FM, Morgan TM, Nelson PS, Lin DW, Wagner AA. Waisman Malaret AJ, et al. Among authors: nelson ps. J Urol. 2022 Apr;207(4):805-813. doi: 10.1097/JU.0000000000002354. Epub 2021 Dec 2. J Urol. 2022. PMID: 34854745 Free PMC article.
We sought to compare clinical outcomes of men with GG1 and GG2 prostate cancer undergoing AS in a large prospective North American cohort. MATERIALS AND METHODS: Participants were prospectively enrolled in an AS study with protocol-directed followup at 10 centers in …
We sought to compare clinical outcomes of men with GG1 and GG2 prostate cancer undergoing AS in a large prospective North Amer …
Subtype heterogeneity and epigenetic convergence in neuroendocrine prostate cancer.
Cejas P, Xie Y, Font-Tello A, Lim K, Syamala S, Qiu X, Tewari AK, Shah N, Nguyen HM, Patel RA, Brown L, Coleman I, Hackeng WM, Brosens L, Dreijerink KMA, Ellis L, Alaiwi SA, Seo JH, Baca S, Beltran H, Khani F, Pomerantz M, Dall'Agnese A, Crowdis J, Van Allen EM, Bellmunt J, Morrisey C, Nelson PS, DeCaprio J, Farago A, Dyson N, Drapkin B, Liu XS, Freedman M, Haffner MC, Corey E, Brown M, Long HW. Cejas P, et al. Among authors: nelson ps. Nat Commun. 2021 Oct 1;12(1):5775. doi: 10.1038/s41467-021-26042-z. Nat Commun. 2021. PMID: 34599169 Free PMC article.
With a particular focus on treatment emergent neuroendocrine prostate cancer (NEPC), we analyze cell lines, patient-derived xenograft (PDX) models and human clinical samples to show the existence of two distinct NEPC subtypes based on the expression of the neuronal …
With a particular focus on treatment emergent neuroendocrine prostate cancer (NEPC), we analyze cell lines, patient-derived xe …
Computational modeling identifies multitargeted kinase inhibitors as effective therapies for metastatic, castration-resistant prostate cancer.
Bello T, Paindelli C, Diaz-Gomez LA, Melchiorri A, Mikos AG, Nelson PS, Dondossola E, Gujral TS. Bello T, et al. Among authors: nelson ps. Proc Natl Acad Sci U S A. 2021 Oct 5;118(40):e2103623118. doi: 10.1073/pnas.2103623118. Epub 2021 Sep 30. Proc Natl Acad Sci U S A. 2021. PMID: 34593636 Free PMC article.
Castration-resistant prostate cancer (CRPC) is an advanced subtype of prostate cancer with limited therapeutic options. ...
Castration-resistant prostate cancer (CRPC) is an advanced subtype of prostate cancer with limited therapeutic o …
Efficacy of systemic therapies in men with metastatic castration resistant prostate cancer harboring germline ATM versus BRCA2 mutations.
Sokolova AO, Marshall CH, Lozano R, Gulati R, Ledet EM, De Sarkar N, Grivas P, Higano CS, Montgomery B, Nelson PS, Olmos D, Sokolov V, Schweizer MT, Yezefski TA, Yu EY, Paller CJ, Sartor O, Castro E, Antonarakis ES, Cheng HH. Sokolova AO, et al. Among authors: nelson ps. Prostate. 2021 Dec;81(16):1382-1389. doi: 10.1002/pros.24236. Epub 2021 Sep 13. Prostate. 2021. PMID: 34516663 Free PMC article.
BACKGROUND: Among men with metastatic prostate cancer, about 10% have germline alterations in DNA damage response genes. Most studies have examined BRCA2 alone or an aggregate of BRCA1/2 and ATM. ...The objective of this study is to determine whether response to …
BACKGROUND: Among men with metastatic prostate cancer, about 10% have germline alterations in DNA damage response genes. Most …
Treatment in the absence of disease reclassification among men on active surveillance for prostate cancer.
Kirk PS, Zhu K, Zheng Y, Newcomb LF, Schenk JM, Brooks JD, Carroll PR, Dash A, Ellis WJ, Filson CP, Gleave ME, Liss M, Martin F, McKenney JK, Morgan TM, Nelson PS, Thompson IM, Wagner AA, Lin DW, Gore JL. Kirk PS, et al. Among authors: nelson ps. Cancer. 2022 Jan 15;128(2):269-274. doi: 10.1002/cncr.33911. Epub 2021 Sep 13. Cancer. 2022. PMID: 34516660 Free PMC article.
METHODS: This study identified 1789 men in the Canary Prostate Cancer Active Surveillance Study cohort enrolled as of 2020 with a median follow-up of 5.6 years. ...LAY SUMMARY: This analysis of men on active surveillance for prostate cancer shows that …
METHODS: This study identified 1789 men in the Canary Prostate Cancer Active Surveillance Study cohort enrolled as of 2020 wit …
Effect of Diagnostic Biopsy Practice Location on Grade/Volume Reclassification in Active Surveillance for Prostate Cancer: A Multicenter Analysis from the Canary PASS Cohort.
Waisman Malaret AJ, Chang P, Newcomb L, Faino A, Zheng Y, Zhu K, McKenney JK, Brooks JD, Dash A, Ellis WJ, Filson CP, Gleave M, Liss M, Martin FM, Morgan T, Carroll P, Nelson P, Lin DW, Wagner AA. Waisman Malaret AJ, et al. Among authors: nelson p. Urol Pract. 2021 Sep;8(5):576-582. doi: 10.1097/UPJ.0000000000000245. Epub 2021 Jun 25. Urol Pract. 2021. PMID: 37145399
INTRODUCTION: We analyzed the Canary Prostate Cancer Active Surveillance (PASS) cohort to determine if patients who had diagnostic biopsy at an off-site practice were at higher risk of reclassification than those having their diagnostic biopsy at a PASS site. ...We …
INTRODUCTION: We analyzed the Canary Prostate Cancer Active Surveillance (PASS) cohort to determine if patients who had diagno …
Reciprocal YAP1 loss and INSM1 expression in neuroendocrine prostate cancer.
Asrani K, Torres AF, Woo J, Vidotto T, Tsai HK, Luo J, Corey E, Hanratty B, Coleman I, Yegnasubramanian S, De Marzo AM, Nelson PS, Haffner MC, Lotan TL. Asrani K, et al. Among authors: nelson ps. J Pathol. 2021 Dec;255(4):425-437. doi: 10.1002/path.5781. Epub 2021 Sep 23. J Pathol. 2021. PMID: 34431104 Free PMC article.
Neuroendocrine prostate cancer (NEPC) is a rare but aggressive histologic variant of prostate cancer that responds poorly to androgen deprivation therapy. ...In prostate cancer cell lines, transgenic mouse models, and human prostate …
Neuroendocrine prostate cancer (NEPC) is a rare but aggressive histologic variant of prostate cancer that respon …
Circulating and Intratumoral Adrenal Androgens Correlate with Response to Abiraterone in Men with Castration-Resistant Prostate Cancer.
Mostaghel EA, Marck BT, Kolokythas O, Chew F, Yu EY, Schweizer MT, Cheng HH, Kantoff PW, Balk SP, Taplin ME, Sharifi N, Matsumoto AM, Nelson PS, Montgomery RB. Mostaghel EA, et al. Among authors: nelson ps. Clin Cancer Res. 2021 Nov 1;27(21):6001-6011. doi: 10.1158/1078-0432.CCR-21-1819. Epub 2021 Aug 18. Clin Cancer Res. 2021. PMID: 34407973 Free PMC article. Clinical Trial.
PURPOSE: In metastatic castration-resistant prostate cancer (mCRPC) low serum androgens prior to starting abiraterone acetate (AA) is associated with more rapid progression. We evaluated the effect of AA on androgens in castration-resistant prostate cancer …
PURPOSE: In metastatic castration-resistant prostate cancer (mCRPC) low serum androgens prior to starting abiraterone acetate …
RNA Splicing Factors SRRM3 and SRRM4 Distinguish Molecular Phenotypes of Castration-Resistant Neuroendocrine Prostate Cancer.
Labrecque MP, Brown LG, Coleman IM, Lakely B, Brady NJ, Lee JK, Nguyen HM, Li D, Hanratty B, Haffner MC, Rickman DS, True LD, Lin DW, Lam HM, Alumkal JJ, Corey E, Nelson PS, Morrissey C. Labrecque MP, et al. Among authors: nelson ps. Cancer Res. 2021 Sep 15;81(18):4736-4750. doi: 10.1158/0008-5472.CAN-21-0307. Epub 2021 Jul 26. Cancer Res. 2021. PMID: 34312180 Free PMC article.
Neuroendocrine (NE) differentiation in metastatic castration-resistant prostate cancer (mCRPC) is an increasingly common clinical feature arising from cellular plasticity. We recently characterized two mCRPC phenotypes with NE features: androgen receptor (AR)-positi …
Neuroendocrine (NE) differentiation in metastatic castration-resistant prostate cancer (mCRPC) is an increasingly common clini …
Multiplexed functional genomic analysis of 5' untranslated region mutations across the spectrum of prostate cancer.
Lim Y, Arora S, Schuster SL, Corey L, Fitzgibbon M, Wladyka CL, Wu X, Coleman IM, Delrow JJ, Corey E, True LD, Nelson PS, Ha G, Hsieh AC. Lim Y, et al. Among authors: nelson ps. Nat Commun. 2021 Jul 9;12(1):4217. doi: 10.1038/s41467-021-24445-6. Nat Commun. 2021. PMID: 34244513 Free PMC article.
Here we develop a high-throughput multi-layer functional genomics method called PLUMAGE (Pooled full-length UTR Multiplex Assay on Gene Expression) to quantify the molecular consequences of somatic 5' UTR mutations in human prostate cancer. We show that 5' UTR mutat …
Here we develop a high-throughput multi-layer functional genomics method called PLUMAGE (Pooled full-length UTR Multiplex Assay on Gene Expr …
BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program.
Kim DH, Sun D, Storck WK, Welker Leng K, Jenkins C, Coleman DJ, Sampson D, Guan X, Kumaraswamy A, Rodansky ES, Urrutia JA, Schwartzman JA, Zhang C, Beltran H, Labrecque MP, Morrissey C, Lucas JM, Coleman IM, Nelson PS, Corey E, Handelman SK, Sexton JZ, Aggarwal R, Abida W, Feng FY, Small EJ, Spratt DE, Bankhead A 3rd, Rao A, Gesner EM, Attwell S, Lakhotia S, Campeau E, Yates JA, Xia Z, Alumkal JJ. Kim DH, et al. Among authors: nelson ps. Clin Cancer Res. 2021 Sep 1;27(17):4923-4936. doi: 10.1158/1078-0432.CCR-20-4968. Epub 2021 Jun 18. Clin Cancer Res. 2021. PMID: 34145028 Free PMC article.
PURPOSE: Lineage plasticity in prostate cancer-most commonly exemplified by loss of androgen receptor (AR) signaling and a switch from a luminal to alternate differentiation program-is now recognized as a treatment resistance mechanism. Lineage plasticity is a spect …
PURPOSE: Lineage plasticity in prostate cancer-most commonly exemplified by loss of androgen receptor (AR) signaling and a swi …
Selective androgen receptor modulators activate the canonical prostate cancer androgen receptor program and repress cancer growth.
Nyquist MD, Ang LS, Corella A, Coleman IM, Meers MP, Christiani AJ, Pierce C, Janssens DH, Meade HE, Bose A, Brady L, Howard T, De Sarkar N, Frank SB, Dumpit RF, Dalton JT, Corey E, Plymate SR, Haffner MC, Mostaghel EA, Nelson PS. Nyquist MD, et al. Among authors: nelson ps. J Clin Invest. 2021 Jun 15;131(12):e151719. doi: 10.1172/JCI151719. J Clin Invest. 2021. PMID: 34128479 Free PMC article. No abstract available.
Concordance of DNA Repair Gene Mutations in Paired Primary Prostate Cancer Samples and Metastatic Tissue or Cell-Free DNA.
Schweizer MT, Sivakumar S, Tukachinsky H, Coleman I, De Sarkar N, Yu EY, Konnick EQ, Nelson PS, Pritchard CC, Montgomery B. Schweizer MT, et al. Among authors: nelson ps. JAMA Oncol. 2021 Jun 4;7(9):1-5. doi: 10.1001/jamaoncol.2021.2350. Online ahead of print. JAMA Oncol. 2021. PMID: 34086042 Free PMC article.
We hypothesized that most DDR alterations represent truncal events in prostate cancer and that primary tissue would faithfully reflect mutations found in cell-free circulating tumor DNA (ctDNA) and/or metastatic tissue. ...Sequencing data from 3 cohorts were analyze …
We hypothesized that most DDR alterations represent truncal events in prostate cancer and that primary tissue would faithfully …
A MYC and RAS co-activation signature in localized prostate cancer drives bone metastasis and castration resistance.
Arriaga JM, Panja S, Alshalalfa M, Zhao J, Zou M, Giacobbe A, Madubata CJ, Kim JY, Rodriguez A, Coleman I, Virk RK, Hibshoosh H, Ertunc O, Ozbek B, Fountain J, Jeffrey Karnes R, Luo J, Antonarakis ES, Nelson PS, Feng FY, Rubin MA, De Marzo AM, Rabadan R, Sims PA, Mitrofanova A, Abate-Shen C. Arriaga JM, et al. Among authors: nelson ps. Nat Cancer. 2020 Nov;1(11):1082-1096. doi: 10.1038/s43018-020-00125-0. Epub 2020 Oct 19. Nat Cancer. 2020. PMID: 34085047 Free PMC article.
Understanding the intricacies of lethal prostate cancer poses specific challenges due to difficulties in accurate modeling of metastasis in vivo. Here we show that NPK (EYFP) mice (for Nkx3.1 (CreERT2/+) ; Pten (flox/flox) ; Kras (LSL-G12D/+) ; R26R-CAG-(LSL-EYFP/+) …
Understanding the intricacies of lethal prostate cancer poses specific challenges due to difficulties in accurate modeling of …
Selective androgen receptor modulators activate the canonical prostate cancer androgen receptor program and repress cancer growth.
Nyquist MD, Ang LS, Corella A, Coleman IM, Meers MP, Christiani AJ, Pierce C, Janssens DH, Meade HE, Bose A, Brady L, Howard T, De Sarkar N, Frank SB, Dumpit RF, Dalton JT, Corey E, Plymate SR, Haffner MC, Mostaghel EA, Nelson PS. Nyquist MD, et al. Among authors: nelson ps. J Clin Invest. 2021 May 17;131(10):e146777. doi: 10.1172/JCI146777. J Clin Invest. 2021. PMID: 33998604 Free PMC article.
Prostate cancer (PC) is driven by androgen receptor (AR) activity, a master regulator of prostate development and homeostasis. ...
Prostate cancer (PC) is driven by androgen receptor (AR) activity, a master regulator of prostate development and homeo …
Correction: Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors.
Zhu Y, Dalrymple SL, Coleman I, Zheng SL, Xu J, Hooper JE, Antonarakis ES, De Marzo AM, Meeker AK, Nelson PS, Isaacs WB, Denmeade SR, Luo J, Brennen WN, Isaacs JT. Zhu Y, et al. Among authors: nelson ps. Oncogene. 2021 Jun;40(22):3914-3916. doi: 10.1038/s41388-021-01805-6. Oncogene. 2021. PMID: 33958727 No abstract available.
Phase II Multicenter Study of Enzalutamide in Metastatic Castration-Resistant Prostate Cancer to Identify Mechanisms Driving Resistance.
McKay RR, Kwak L, Crowdis JP, Sperger JM, Zhao SG, Xie W, Werner L, Lis RT, Zhang Z, Wei XX, Lang JM, Van Allen EM, Bhatt RS, Yu EY, Nelson PS, Bubley GJ, Montgomery RB, Taplin ME. McKay RR, et al. Among authors: nelson ps. Clin Cancer Res. 2021 Jul 1;27(13):3610-3619. doi: 10.1158/1078-0432.CCR-20-4616. Epub 2021 Apr 13. Clin Cancer Res. 2021. PMID: 33849963 Free PMC article. Clinical Trial.
PURPOSE: Enzalutamide is a second-generation androgen receptor (AR) inhibitor that has improved overall survival (OS) in metastatic castration-resistant prostate cancer (CRPC). However, nearly all patients develop resistance. We designed a phase II multicenter study …
PURPOSE: Enzalutamide is a second-generation androgen receptor (AR) inhibitor that has improved overall survival (OS) in metastatic castrati …
Author Correction: MTOR regulates the pro-tumorigenic senescence-associated secretory phenotype by promoting IL1A translation.
Laberge RM, Sun Y, Orjalo AV, Patil CK, Freund A, Zhou L, Curran SC, Davalos AR, Wilson-Edell KA, Liu S, Limbad C, Demaria M, Li P, Hubbard GB, Ikeno Y, Javors M, Desprez PY, Benz CC, Kapahi P, Nelson PS, Campisi J. Laberge RM, et al. Among authors: nelson ps. Nat Cell Biol. 2021 May;23(5):564-565. doi: 10.1038/s41556-021-00655-4. Nat Cell Biol. 2021. PMID: 33824512 No abstract available.
The heterogeneity of prostate cancers lacking AR activity will require diverse treatment approaches.
Labrecque MP, Alumkal JJ, Coleman IM, Nelson PS, Morrissey C. Labrecque MP, et al. Among authors: nelson ps. Endocr Relat Cancer. 2021 Jul 15;28(8):T51-T66. doi: 10.1530/ERC-21-0002. Endocr Relat Cancer. 2021. PMID: 33792558 Free PMC article. Review.
The use of androgen deprivation therapy and second-line anti-androgens in prostate cancer has led to the emergence of tumors employing multiple androgen receptor (AR)-dependent and AR-independent mechanisms to resist AR-targeted therapies in castration-resistant …
The use of androgen deprivation therapy and second-line anti-androgens in prostate cancer has led to the emergence of tumors e …
Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer.
Baca SC, Takeda DY, Seo JH, Hwang J, Ku SY, Arafeh R, Arnoff T, Agarwal S, Bell C, O'Connor E, Qiu X, Alaiwi SA, Corona RI, Fonseca MAS, Giambartolomei C, Cejas P, Lim K, He M, Sheahan A, Nassar A, Berchuck JE, Brown L, Nguyen HM, Coleman IM, Kaipainen A, De Sarkar N, Nelson PS, Morrissey C, Korthauer K, Pomerantz MM, Ellis L, Pasaniuc B, Lawrenson K, Kelly K, Zoubeidi A, Hahn WC, Beltran H, Long HW, Brown M, Corey E, Freedman ML. Baca SC, et al. Among authors: nelson ps. Nat Commun. 2021 Mar 30;12(1):1979. doi: 10.1038/s41467-021-22139-7. Nat Commun. 2021. PMID: 33785741 Free PMC article.
Lineage plasticity, the ability of a cell to alter its identity, is an increasingly common mechanism of adaptive resistance to targeted therapy in cancer. An archetypal example is the development of neuroendocrine prostate cancer (NEPC) after treatment of …
Lineage plasticity, the ability of a cell to alter its identity, is an increasingly common mechanism of adaptive resistance to targeted ther …
Targeting backdoor androgen synthesis through AKR1C3 inhibition: A presurgical hormonal ablative neoadjuvant trial in high-risk localized prostate cancer.
Graham LS, True LD, Gulati R, Schade GR, Wright J, Grivas P, Yezefski T, Nega K, Alexander K, Hou WM, Yu EY, Montgomery B, Mostaghel EA, Matsumoto AA, Marck B, Sharifi N, Ellis WJ, Reder NP, Lin DW, Nelson PS, Schweizer MT. Graham LS, et al. Among authors: nelson ps. Prostate. 2021 May;81(7):418-426. doi: 10.1002/pros.24118. Epub 2021 Mar 23. Prostate. 2021. PMID: 33755225 Free PMC article.
BACKGROUND: Localized prostate cancers (PCs) may resist neoadjuvant androgen receptor (AR)-targeted therapies as a result of persistent intraprostatic androgens arising through upregulation of steroidogenic enzymes. ...RESULTS: Twenty patients were evaluable for the primar …
BACKGROUND: Localized prostate cancers (PCs) may resist neoadjuvant androgen receptor (AR)-targeted therapies as a result of persiste …
Resistance to androgen receptor signaling inhibition does not necessitate development of neuroendocrine prostate cancer.
Brennen WN, Zhu Y, Coleman IM, Dalrymple SL, Antony L, Patel RA, Hanratty B, Chikarmane R, Meeker AK, Zheng SL, Hooper JE, Luo J, De Marzo AM, Corey E, Xu J, Yegnasubramanian S, Haffner MC, Nelson PS, Nelson WG, Isaacs WB, Isaacs JT. Brennen WN, et al. Among authors: nelson ps. JCI Insight. 2021 Apr 22;6(8):e146827. doi: 10.1172/jci.insight.146827. JCI Insight. 2021. PMID: 33724955 Free PMC article.
Resistance to AR signaling inhibitors (ARSis) in a subset of metastatic castration-resistant prostate cancers (mCRPCs) occurs with the emergence of AR- neuroendocrine prostate cancer (NEPC) coupled with mutations/deletions in PTEN, TP53, and RB1 and the overe …
Resistance to AR signaling inhibitors (ARSis) in a subset of metastatic castration-resistant prostate cancers (mCRPCs) occurs with th …
Inter- and intra-tumor heterogeneity of metastatic prostate cancer determined by digital spatial gene expression profiling.
Brady L, Kriner M, Coleman I, Morrissey C, Roudier M, True LD, Gulati R, Plymate SR, Zhou Z, Birditt B, Meredith R, Geiss G, Hoang M, Beechem J, Nelson PS. Brady L, et al. Among authors: nelson ps. Nat Commun. 2021 Mar 3;12(1):1426. doi: 10.1038/s41467-021-21615-4. Nat Commun. 2021. PMID: 33658518 Free PMC article.
Metastatic prostate cancer (mPC) comprises a spectrum of diverse phenotypes. However, the extent of inter- and intra-tumor heterogeneity is not established. ...
Metastatic prostate cancer (mPC) comprises a spectrum of diverse phenotypes. However, the extent of inter- and intra-tumor het …
MAPK4 promotes prostate cancer by concerted activation of androgen receptor and AKT.
Shen T, Wang W, Zhou W, Coleman I, Cai Q, Dong B, Ittmann MM, Creighton CJ, Bian Y, Meng Y, Rowley DR, Nelson PS, Moore DD, Yang F. Shen T, et al. Among authors: nelson ps. J Clin Invest. 2021 Feb 15;131(4):e135465. doi: 10.1172/JCI135465. J Clin Invest. 2021. PMID: 33586682 Free PMC article.
Prostate cancer (PCa) is the second leading cause of cancer death in American men. Androgen receptor (AR) signaling is essential for PCa cell growth/survival and remains a key therapeutic target for lethal castration-resistant PCa (CRPC). ...
Prostate cancer (PCa) is the second leading cause of cancer death in American men. Androgen receptor (AR) signaling is …
Correction to: Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors.
Zhu Y, Dalrymple SL, Coleman I, Zheng SL, Xu J, Hooper JE, Antonarakis ES, De Marzo AM, Meeker AK, Nelson PS, Isaacs WB, Denmeade SR, Luo J, Brennen WN, Isaacs JT. Zhu Y, et al. Among authors: nelson ps. Oncogene. 2021 Mar;40(11):2148. doi: 10.1038/s41388-021-01640-9. Oncogene. 2021. PMID: 33564077 No abstract available.
Cabozantinib can block growth of neuroendocrine prostate cancer patient-derived xenografts by disrupting tumor vasculature.
Labrecque MP, Brown LG, Coleman IM, Nguyen HM, Lin DW, Corey E, Nelson PS, Morrissey C. Labrecque MP, et al. Among authors: nelson ps. PLoS One. 2021 Jan 20;16(1):e0245602. doi: 10.1371/journal.pone.0245602. eCollection 2021. PLoS One. 2021. PMID: 33471819 Free PMC article.
With the advent of potent second-line anti-androgen therapy, we and others have observed an increased incidence of androgen receptor (AR)-null small cell or neuroendocrine prostate cancer (SCNPC) in metastatic castration-resistant prostate cancer (mCRP …
With the advent of potent second-line anti-androgen therapy, we and others have observed an increased incidence of androgen receptor (AR)-nu …
Antibody profiling of patients with prostate cancer reveals differences in antibody signatures among disease stages.
Potluri HK, Ng TL, Newton MA, Zhang J, Maher CA, Nelson PS, McNeel DG. Potluri HK, et al. Among authors: nelson ps. J Immunother Cancer. 2020 Dec;8(2):e001510. doi: 10.1136/jitc-2020-001510. J Immunother Cancer. 2020. PMID: 33335027 Free PMC article.
BACKGROUND: Previous studies of prostate cancer autoantibodies have largely focused on diagnostic applications. So far, there have been no reports attempting to more comprehensively profile the landscape of prostate cancer-associated antibodies. ...The …
BACKGROUND: Previous studies of prostate cancer autoantibodies have largely focused on diagnostic applications. So far, there …
Genomic and phenotypic heterogeneity in prostate cancer.
Haffner MC, Zwart W, Roudier MP, True LD, Nelson WG, Epstein JI, De Marzo AM, Nelson PS, Yegnasubramanian S. Haffner MC, et al. Among authors: nelson ps. Nat Rev Urol. 2021 Feb;18(2):79-92. doi: 10.1038/s41585-020-00400-w. Epub 2020 Dec 16. Nat Rev Urol. 2021. PMID: 33328650 Free PMC article. Review.
From a clinical, morphological and molecular perspective, prostate cancer is a heterogeneous disease. Primary prostate cancers are often multifocal, having topographically and morphologically distinct tumour foci. ...This finding demonstrates that multiple ge …
From a clinical, morphological and molecular perspective, prostate cancer is a heterogeneous disease. Primary prostate …
Regulation of CEACAM5 and Therapeutic Efficacy of an Anti-CEACAM5-SN38 Antibody-drug Conjugate in Neuroendocrine Prostate Cancer.
DeLucia DC, Cardillo TM, Ang L, Labrecque MP, Zhang A, Hopkins JE, De Sarkar N, Coleman I, da Costa RMG, Corey E, True LD, Haffner MC, Schweizer MT, Morrissey C, Nelson PS, Lee JK. DeLucia DC, et al. Among authors: nelson ps. Clin Cancer Res. 2021 Feb 1;27(3):759-774. doi: 10.1158/1078-0432.CCR-20-3396. Epub 2020 Nov 16. Clin Cancer Res. 2021. PMID: 33199493 Free PMC article.
PURPOSE: Neuroendocrine prostate cancer (NEPC) is an aggressive form of castration-resistant prostate cancer (CRPC) for which effective therapies are lacking. ...Here we investigated the scope of CEACAM5 expression in end-stage prostate cance …
PURPOSE: Neuroendocrine prostate cancer (NEPC) is an aggressive form of castration-resistant prostate cancer (CR …
Association of Clonal Hematopoiesis in DNA Repair Genes With Prostate Cancer Plasma Cell-free DNA Testing Interference.
Jensen K, Konnick EQ, Schweizer MT, Sokolova AO, Grivas P, Cheng HH, Klemfuss NM, Beightol M, Yu EY, Nelson PS, Montgomery B, Pritchard CC. Jensen K, et al. Among authors: nelson ps. JAMA Oncol. 2021 Jan 1;7(1):107-110. doi: 10.1001/jamaoncol.2020.5161. JAMA Oncol. 2021. PMID: 33151258 Free PMC article.
MAIN OUTCOMES AND MEASURES: Prevalence and gene spectrum of CHIP interference in patients with prostate cancer undergoing cfDNA testing. RESULTS: We detected CHIP variants at 2% or more variant fraction in cfDNA from 13 of 69 men with prostate cancer ( …
MAIN OUTCOMES AND MEASURES: Prevalence and gene spectrum of CHIP interference in patients with prostate cancer undergoing cfDN …
Deconstructing tumor heterogeneity: the stromal perspective.
Vickman RE, Faget DV, Beachy P, Beebe D, Bhowmick NA, Cukierman E, Deng WM, Granneman JG, Hildesheim J, Kalluri R, Lau KS, Lengyel E, Lundeberg J, Moscat J, Nelson PS, Pietras K, Politi K, Puré E, Scherz-Shouval R, Sherman MH, Tuveson D, Weeraratna AT, White RM, Wong MH, Woodhouse EC, Zheng Y, Hayward SW, Stewart SA. Vickman RE, et al. Among authors: nelson ps. Oncotarget. 2020 Oct 6;11(40):3621-3632. doi: 10.18632/oncotarget.27736. eCollection 2020 Oct 6. Oncotarget. 2020. PMID: 33088423 Free PMC article.
FOXA2 promotes prostate cancer growth in the bone.
Connelly ZM, Jin R, Zhang J, Yang S, Cheng S, Shi M, Cates JM, Shi R, DeGraff DJ, Nelson PS, Liu Y, Morrissey C, Corey E, Yu X. Connelly ZM, et al. Among authors: nelson ps. Am J Transl Res. 2020 Sep 15;12(9):5619-5629. eCollection 2020. Am J Transl Res. 2020. PMID: 33042443 Free PMC article.
Bone metastasis frequently occurs in advanced-stage prostate cancer (PCa) patients. Understanding the mechanisms that promote PCa-mediated bone destruction is important for the identification of therapeutic targets against this lethal disease. ...
Bone metastasis frequently occurs in advanced-stage prostate cancer (PCa) patients. Understanding the mechanisms that promote …
Dickkopf-1 Can Lead to Immune Evasion in Metastatic Castration-Resistant Prostate Cancer.
Wise DR, Schneider JA, Armenia J, Febles VA, McLaughlin B, Brennan R, Thoren KL, Abida W, Sfanos KS, De Marzo AM, Yegnasubramanian S, Fox JJ, Haas M, Heath H, Kagey MH, Newman W, Sirard CA, Fleisher M, Morris MJ, Chen Y, Larson SM, Haffner MC, Nelson PS, Schultz N, Garabedian MJ, Scher HI, Logan SK, Sawyers CL; International SU2C/PCF Prostate Cancer Dream Team. Wise DR, et al. Among authors: nelson ps. JCO Precis Oncol. 2020 Sep 29;4:PO.20.00097. doi: 10.1200/PO.20.00097. eCollection 2020. JCO Precis Oncol. 2020. PMID: 33015525 Free PMC article.
PURPOSE: Metastatic castration-resistant prostate cancer (mCRPC) with low androgen receptor (AR) and without neuroendocrine signaling, termed double-negative prostate cancer (DNPC), is increasingly prevalent in patients treated with AR signaling inhibi …
PURPOSE: Metastatic castration-resistant prostate cancer (mCRPC) with low androgen receptor (AR) and without neuroendocrine si …
Impact of mutations in homologous recombination repair genes on treatment outcomes for metastatic castration resistant prostate cancer.
Carlson AS, Acevedo RI, Lim DM, Gulati R, Gawne A, Sokolova AO, Cheng HH, Nelson PS, Montgomery RB, Yu EY, Schweizer MT. Carlson AS, et al. Among authors: nelson ps. PLoS One. 2020 Sep 30;15(9):e0239686. doi: 10.1371/journal.pone.0239686. eCollection 2020. PLoS One. 2020. PMID: 32997692 Free PMC article.
INTRODUCTION: A significant proportion of patients with metastatic castration-resistant prostate cancer (mCRPC) harbor mutations in homologous recombination (HR) repair genes, with some of these mutations associating with increased tumor susceptibility to poly(ADP-r …
INTRODUCTION: A significant proportion of patients with metastatic castration-resistant prostate cancer (mCRPC) harbor mutatio …
Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors.
Zhu Y, Dalrymple SL, Coleman I, Zheng SL, Xu J, Hooper JE, Antonarakis ES, De Marzo AM, Meeker AK, Nelson PS, Isaacs WB, Denmeade SR, Luo J, Brennen WN, Isaacs JT. Zhu Y, et al. Among authors: nelson ps. Oncogene. 2020 Nov;39(45):6935-6949. doi: 10.1038/s41388-020-01479-6. Epub 2020 Sep 28. Oncogene. 2020. PMID: 32989253 Free PMC article.
The role of truncated androgen receptor splice variant-7 (AR-V7) in prostate cancer biology is an unresolved question. Is it simply a marker of resistance to 2nd-generation androgen receptor signaling inhibitors (ARSi) like abiraterone acetate (Abi) and enzalutamide …
The role of truncated androgen receptor splice variant-7 (AR-V7) in prostate cancer biology is an unresolved question. Is it s …
Tailoring Intensity of Active Surveillance for Low-Risk Prostate Cancer Based on Individualized Prediction of Risk Stability.
Cooperberg MR, Zheng Y, Faino AV, Newcomb LF, Zhu K, Cowan JE, Brooks JD, Dash A, Gleave ME, Martin F, Morgan TM, Nelson PS, Thompson IM, Wagner AA, Carroll PR, Lin DW. Cooperberg MR, et al. Among authors: nelson ps. JAMA Oncol. 2020 Oct 1;6(10):e203187. doi: 10.1001/jamaoncol.2020.3187. Epub 2020 Oct 8. JAMA Oncol. 2020. PMID: 32852532 Free PMC article.
Men with prostate cancer managed with active surveillance from 9 North American academic medical centers were enrolled. ...CONCLUSIONS AND RELEVANCE: In this study, among men with low-risk prostate cancer, heterogeneity prevailed in risk of subsequent …
Men with prostate cancer managed with active surveillance from 9 North American academic medical centers were enrolled. ...CON …
Imaging Fibroblast Activation Protein Alpha Improves Diagnosis of Metastatic Prostate Cancer with Positron Emission Tomography.
Hintz HM, Gallant JP, Vander Griend DJ, Coleman IM, Nelson PS, LeBeau AM. Hintz HM, et al. Among authors: nelson ps. Clin Cancer Res. 2020 Sep 15;26(18):4882-4891. doi: 10.1158/1078-0432.CCR-20-1358. Epub 2020 Jul 7. Clin Cancer Res. 2020. PMID: 32636317 Free PMC article.
PURPOSE: Metastatic castration-resistant prostate cancer (mCRPC) is a lethal, heterogeneous disease with few therapeutic strategies that significantly prolong survival. ...Genomic and IHC analyses were performed to investigate FAP expression in prostate ca …
PURPOSE: Metastatic castration-resistant prostate cancer (mCRPC) is a lethal, heterogeneous disease with few therapeutic strat …
HPV16 induces penile intraepithelial neoplasia and squamous cell carcinoma in transgenic mice: first mouse model for HPV-related penile cancer.
Medeiros-Fonseca B, Mestre VF, Estêvão D, Sánchez DF, Cañete-Portillo S, Fernández-Nestosa MJ, Casaca F, Silva S, Brito H, Félix A, Medeiros R, Colaço B, Oliveira PA, Bastos MM, Nelson PS, Vakar-Lopez F, Gaivão I, Brito L, Lopes C, Cubilla AL, Gil da Costa RM. Medeiros-Fonseca B, et al. Among authors: nelson ps. J Pathol. 2020 Aug;251(4):411-419. doi: 10.1002/path.5475. J Pathol. 2020. PMID: 32488868
Penile cancer is an under-studied disease that occurs more commonly in developing countries and 30-50% of cases show high-risk human papillomavirus (HPV) infection. ...Here, we report the first mouse model for HPV-related penile cancer. Ten-week-old mice expressing …
Penile cancer is an under-studied disease that occurs more commonly in developing countries and 30-50% of cases show high-risk human …
Targeting RET Kinase in Neuroendocrine Prostate Cancer.
VanDeusen HR, Ramroop JR, Morel KL, Bae SY, Sheahan AV, Sychev Z, Lau NA, Cheng LC, Tan VM, Li Z, Petersen A, Lee JK, Park JW, Yang R, Hwang JH, Coleman I, Witte ON, Morrissey C, Corey E, Nelson PS, Ellis L, Drake JM. VanDeusen HR, et al. Among authors: nelson ps. Mol Cancer Res. 2020 Aug;18(8):1176-1188. doi: 10.1158/1541-7786.MCR-19-1245. Epub 2020 May 27. Mol Cancer Res. 2020. PMID: 32461304 Free PMC article.
The increased treatment of metastatic castration-resistant prostate cancer (mCRPC) with second-generation antiandrogen therapies (ADT) has coincided with a greater incidence of lethal, aggressive variant prostate cancer (AVPC) tumors that have lost dep …
The increased treatment of metastatic castration-resistant prostate cancer (mCRPC) with second-generation antiandrogen therapi …
Combined TP53 and RB1 Loss Promotes Prostate Cancer Resistance to a Spectrum of Therapeutics and Confers Vulnerability to Replication Stress.
Nyquist MD, Corella A, Coleman I, De Sarkar N, Kaipainen A, Ha G, Gulati R, Ang L, Chatterjee P, Lucas J, Pritchard C, Risbridger G, Isaacs J, Montgomery B, Morrissey C, Corey E, Nelson PS. Nyquist MD, et al. Among authors: nelson ps. Cell Rep. 2020 May 26;31(8):107669. doi: 10.1016/j.celrep.2020.107669. Cell Rep. 2020. PMID: 32460015 Free PMC article.
Prostate cancers (PCs) with loss of the potent tumor suppressors TP53 and RB1 exhibit poor outcomes. ...
Prostate cancers (PCs) with loss of the potent tumor suppressors TP53 and RB1 exhibit poor outcomes. ...
Mismatch repair deficiency in metastatic prostate cancer: Response to PD-1 blockade and standard therapies.
Graham LS, Montgomery B, Cheng HH, Yu EY, Nelson PS, Pritchard C, Erickson S, Alva A, Schweizer MT. Graham LS, et al. Among authors: nelson ps. PLoS One. 2020 May 26;15(5):e0233260. doi: 10.1371/journal.pone.0233260. eCollection 2020. PLoS One. 2020. PMID: 32453797 Free PMC article.
BACKGROUND: While response rates to anti-PD1 therapy are low in unselected metastatic castration resistant prostate cancer (mCRPC) patients, those with inactivating mutations in mismatch repair (MMR) genes (i.e. ...METHODS: We retrospectively identified patients at …
BACKGROUND: While response rates to anti-PD1 therapy are low in unselected metastatic castration resistant prostate cancer (mC …
Alternative splicing of LSD1+8a in neuroendocrine prostate cancer is mediated by SRRM4.
Coleman DJ, Sampson DA, Sehrawat A, Kumaraswamy A, Sun D, Wang Y, Schwartzman J, Urrutia J, Lee AR, Coleman IM, Nelson PS, Dong X, Morrissey C, Corey E, Xia Z, Yates JA, Alumkal JJ. Coleman DJ, et al. Among authors: nelson ps. Neoplasia. 2020 Jun;22(6):253-262. doi: 10.1016/j.neo.2020.04.002. Epub 2020 May 11. Neoplasia. 2020. PMID: 32403054 Free PMC article.
Neuroendocrine prostate cancer (NEPC) is the most virulent form of prostate cancer. Importantly, our recent work examining metastatic biopsy samples demonstrates NEPC is increasing in frequency. In contrast to prostate adenocarcinomas that expre …
Neuroendocrine prostate cancer (NEPC) is the most virulent form of prostate cancer. Importantly, our recent work …
Magnetic Resonance Imaging for the Detection of High Grade Cancer in the Canary Prostate Active Surveillance Study.
Liss MA, Newcomb LF, Zheng Y, Garcia MP, Filson CP, Boyer H, Brooks JD, Carroll PR, Cooperberg MR, Ellis WJ, Gleave ME, Martin FM, Morgan T, Nelson PS, Wagner AA, Thompson IM Jr, Lin DW. Liss MA, et al. Among authors: nelson ps. J Urol. 2020 Oct;204(4):701-706. doi: 10.1097/JU.0000000000001088. Epub 2020 Apr 28. J Urol. 2020. PMID: 32343189 Free PMC article.
PURPOSE: We investigated the ability of prostate magnetic resonance imaging to detect Gleason Grade Group 2 or greater cancer in a standardized, multi-institutional active surveillance cohort. ...In 194 fusion biopsies higher grade cancer was found in targete …
PURPOSE: We investigated the ability of prostate magnetic resonance imaging to detect Gleason Grade Group 2 or greater cancer …
TMPRSS2 and COVID-19: Serendipity or Opportunity for Intervention?
Stopsack KH, Mucci LA, Antonarakis ES, Nelson PS, Kantoff PW. Stopsack KH, et al. Among authors: nelson ps. Cancer Discov. 2020 Jun;10(6):779-782. doi: 10.1158/2159-8290.CD-20-0451. Epub 2020 Apr 10. Cancer Discov. 2020. PMID: 32276929 Free PMC article. Review.
TMPRSS2 is both the most frequently altered gene in primary prostate cancer and a critical factor enabling cellular infection by coronaviruses, including SARS-CoV-2. ...
TMPRSS2 is both the most frequently altered gene in primary prostate cancer and a critical factor enabling cellular infection …
Comparison of four next generation sequencing platforms for fusion detection: Oncomine by ThermoFisher, AmpliSeq by illumina, FusionPlex by ArcherDX, and QIAseq by QIAGEN.
Qu X, Yeung C, Coleman I, Nelson PS, Fang M. Qu X, et al. Among authors: nelson ps. Cancer Genet. 2020 May;243:11-18. doi: 10.1016/j.cancergen.2020.02.007. Epub 2020 Mar 7. Cancer Genet. 2020. PMID: 32197218 Free PMC article.
We compared four fusion-detection assay platforms on a pilot cohort of 24 prostate cancer samples: (1) Oncomine Comprehensive panel v3; (2) AmpliSeq comprehensive panel v3; (3) The solid tumor panel of FusionPlex; and (4) The human oncology panel of QIAseq. ...
We compared four fusion-detection assay platforms on a pilot cohort of 24 prostate cancer samples: (1) Oncomine Comprehensive …
17-Gene Genomic Prostate Score Test Results in the Canary Prostate Active Surveillance Study (PASS) Cohort.
Lin DW, Zheng Y, McKenney JK, Brown MD, Lu R, Crager M, Boyer H, Tretiakova M, Brooks JD, Dash A, Fabrizio MD, Gleave ME, Kolb S, Liss M, Morgan TM, Thompson IM, Wagner AA, Tsiatis A, Pingitore A, Nelson PS, Newcomb LF. Lin DW, et al. Among authors: nelson ps. J Clin Oncol. 2020 May 10;38(14):1549-1557. doi: 10.1200/JCO.19.02267. Epub 2020 Mar 4. J Clin Oncol. 2020. PMID: 32130059 Free PMC article.
PURPOSE: The 17-gene Oncotype DX Genomic Prostate Score (GPS) test predicts adverse pathology (AP) in patients with low-risk prostate cancer treated with immediate surgery. ...MATERIALS AND METHODS: Diagnostic biopsy tissue was obtained from men enrolled at 8 …
PURPOSE: The 17-gene Oncotype DX Genomic Prostate Score (GPS) test predicts adverse pathology (AP) in patients with low-risk prost …
A comparison of prostate cancer cell transcriptomes in 2D monoculture vs 3D xenografts identify consistent gene expression alterations associated with tumor microenvironments.
Brady L, Gil da Costa RM, Coleman IM, Matson CK, Risk MC, Coleman RT, Nelson PS. Brady L, et al. Among authors: nelson ps. Prostate. 2020 May;80(6):491-499. doi: 10.1002/pros.23963. Epub 2020 Feb 18. Prostate. 2020. PMID: 32068909 Free PMC article.
BACKGROUND: Prostate cancer (PC) research has relied heavily on patient-derived cell lines, which may be used for in vitro (two-dimensional [2D]) studies or cultivated as three-dimensional (3D) xenografts in mice. ...Immunohistochemistry was used to evaluate protein …
BACKGROUND: Prostate cancer (PC) research has relied heavily on patient-derived cell lines, which may be used for in vitro (tw …
Reply by Authors.
Schenk JM, Newcomb LF, Zheng Y, Faino AV, Zhu K, Nyame YA, Brooks JD, Carroll PR, Cooperberg MR, Dash A, Filson CP, Gleave ME, Liss M, Martin FM, Morgan TM, Nelson PS, Thompson IM, Wagner AA, Lin DW. Schenk JM, et al. Among authors: nelson ps. J Urol. 2020 Apr;203(4):733. doi: 10.1097/JU.0000000000000621.02. Epub 2020 Jan 17. J Urol. 2020. PMID: 31951502 No abstract available.
Identification of Therapeutic Vulnerabilities in Small-cell Neuroendocrine Prostate Cancer.
Corella AN, Cabiliza Ordonio MVA, Coleman I, Lucas JM, Kaipainen A, Nguyen HM, Sondheim D, Brown LG, True LD, Lee JK, MacPherson D, Nghiem P, Gulati R, Morrissey C, Corey E, Nelson PS. Corella AN, et al. Among authors: nelson ps. Clin Cancer Res. 2020 Apr 1;26(7):1667-1677. doi: 10.1158/1078-0432.CCR-19-0775. Epub 2019 Dec 5. Clin Cancer Res. 2020. PMID: 31806643 Free PMC article.
PURPOSE: Small-cell neuroendocrine prostate cancer (SCNPC) exhibits an aggressive clinical course and incidence rates seem to be increasing following resistance to potent androgen receptor (AR) antagonists. ...We tested inhibitors to highly upregulated drug targets …
PURPOSE: Small-cell neuroendocrine prostate cancer (SCNPC) exhibits an aggressive clinical course and incidence rates seem to …
Exploitation of CD133 for the Targeted Imaging of Lethal Prostate Cancer.
Glumac PM, Gallant JP, Shapovalova M, Li Y, Murugan P, Gupta S, Coleman IM, Nelson PS, Dehm SM, LeBeau AM. Glumac PM, et al. Among authors: nelson ps. Clin Cancer Res. 2020 Mar 1;26(5):1054-1064. doi: 10.1158/1078-0432.CCR-19-1659. Epub 2019 Nov 15. Clin Cancer Res. 2020. PMID: 31732520 Free PMC article.
PURPOSE: Aggressive variant prostate cancer (AVPC) is a nonandrogen receptor-driven form of disease that arises in men in whom standard-of-care therapies have failed. ...The imaging potential of the CD133-targeted IgG (HA10 IgG) was evaluated in preclinical prost …
PURPOSE: Aggressive variant prostate cancer (AVPC) is a nonandrogen receptor-driven form of disease that arises in men in whom …
African American Race is Not Associated with Risk of Reclassification during Active Surveillance: Results from the Canary Prostate Cancer Active Surveillance Study.
Schenk JM, Newcomb LF, Zheng Y, Faino AV, Zhu K, Nyame YA, Brooks JD, Carroll PR, Cooperberg MR, Dash A, Filson CP, Gleave ME, Liss M, Martin FM, Morgan TM, Nelson PS, Thompson IM, Wagner AA, Lin DW. Schenk JM, et al. Among authors: nelson ps. J Urol. 2020 Apr;203(4):727-733. doi: 10.1097/JU.0000000000000621. Epub 2019 Oct 25. J Urol. 2020. PMID: 31651227 Free PMC article.
MATERIALS AND METHODS: The Canary PASS (Prostate Active Surveillance Study) is a protocol driven, active surveillance cohort with a prespecified prostate specific antigen and surveillance biopsy regimen. ...Active surveillance appears to be an appropriate management …
MATERIALS AND METHODS: The Canary PASS (Prostate Active Surveillance Study) is a protocol driven, active surveillance cohort with a p …
PEG10 Promoter-Driven Expression of Reporter Genes Enables Molecular Imaging of Lethal Prostate Cancer.
Shapovalova M, Lee JK, Li Y, Vander Griend DJ, Coleman IM, Nelson PS, Dehm SM, LeBeau AM. Shapovalova M, et al. Among authors: nelson ps. Cancer Res. 2019 Nov 1;79(21):5668-5680. doi: 10.1158/0008-5472.CAN-19-2181. Epub 2019 Sep 17. Cancer Res. 2019. PMID: 31530569 Free PMC article.
Recently, it was discovered that PEG10 isoforms promote the progression of prostate cancer to a highly lethal androgen receptor (AR)-negative phenotype. The presence of PEG10 in other subtypes of prostate cancer has not been explored and a utility for …
Recently, it was discovered that PEG10 isoforms promote the progression of prostate cancer to a highly lethal androgen recepto …
Molecular determinants of response to high-dose androgen therapy in prostate cancer.
Nyquist MD, Corella A, Mohamad O, Coleman I, Kaipainen A, Kuppers DA, Lucas JM, Paddison PJ, Plymate SR, Nelson PS, Mostaghel EA. Nyquist MD, et al. Among authors: nelson ps. JCI Insight. 2019 Oct 3;4(19):e129715. doi: 10.1172/jci.insight.129715. JCI Insight. 2019. PMID: 31503550 Free PMC article.
Clinical trials of high-dose androgen (HDA) therapy for prostate cancer (PC) have shown promising efficacy but are limited by lack of criteria to identify likely responders. ...
Clinical trials of high-dose androgen (HDA) therapy for prostate cancer (PC) have shown promising efficacy but are limited by …
Testosterone accumulation in prostate cancer cells is enhanced by facilitated diffusion.
Kaipainen A, Zhang A, Gil da Costa RM, Lucas J, Marck B, Matsumoto AM, Morrissey C, True LD, Mostaghel EA, Nelson PS. Kaipainen A, et al. Among authors: nelson ps. Prostate. 2019 Sep;79(13):1530-1542. doi: 10.1002/pros.23874. Epub 2019 Aug 2. Prostate. 2019. PMID: 31376206 Free PMC article.
BACKGROUND: Testosterone is a driver of prostate cancer (PC) growth via ligand-mediated activation of the androgen receptor (AR). Tumors that have escaped systemic androgen deprivation, castration-resistant prostate cancers (CRPC), have measurable intratumora …
BACKGROUND: Testosterone is a driver of prostate cancer (PC) growth via ligand-mediated activation of the androgen receptor (A …
The androgen receptor regulates a druggable translational regulon in advanced prostate cancer.
Liu Y, Horn JL, Banda K, Goodman AZ, Lim Y, Jana S, Arora S, Germanos AA, Wen L, Hardin WR, Yang YC, Coleman IM, Tharakan RG, Cai EY, Uo T, Pillai SPS, Corey E, Morrissey C, Chen Y, Carver BS, Plymate SR, Beronja S, Nelson PS, Hsieh AC. Liu Y, et al. Among authors: nelson ps. Sci Transl Med. 2019 Jul 31;11(503):eaaw4993. doi: 10.1126/scitranslmed.aaw4993. Sci Transl Med. 2019. PMID: 31366581 Free PMC article.
The androgen receptor (AR) is a driver of cellular differentiation and prostate cancer development. An extensive body of work has linked these normal and aberrant cellular processes to mRNA transcription; however, the extent to which AR regulates posttranscriptional …
The androgen receptor (AR) is a driver of cellular differentiation and prostate cancer development. An extensive body of work …
The Role of Lineage Plasticity in Prostate Cancer Therapy Resistance.
Beltran H, Hruszkewycz A, Scher HI, Hildesheim J, Isaacs J, Yu EY, Kelly K, Lin D, Dicker A, Arnold J, Hecht T, Wicha M, Sears R, Rowley D, White R, Gulley JL, Lee J, Diaz Meco M, Small EJ, Shen M, Knudsen K, Goodrich DW, Lotan T, Zoubeidi A, Sawyers CL, Rudin CM, Loda M, Thompson T, Rubin MA, Tawab-Amiri A, Dahut W, Nelson PS. Beltran H, et al. Among authors: nelson ps. Clin Cancer Res. 2019 Dec 1;25(23):6916-6924. doi: 10.1158/1078-0432.CCR-19-1423. Epub 2019 Jul 30. Clin Cancer Res. 2019. PMID: 31363002 Free PMC article.
At present, there is no established therapeutic approach for patients with advanced prostate cancer developing lineage plasticity or small cell neuroendocrine prostate cancer (NEPC) due to knowledge gaps in the underlying biology. ...This Perspective r …
At present, there is no established therapeutic approach for patients with advanced prostate cancer developing lineage plastic …
Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer.
Labrecque MP, Coleman IM, Brown LG, True LD, Kollath L, Lakely B, Nguyen HM, Yang YC, da Costa RMG, Kaipainen A, Coleman R, Higano CS, Yu EY, Cheng HH, Mostaghel EA, Montgomery B, Schweizer MT, Hsieh AC, Lin DW, Corey E, Nelson PS, Morrissey C. Labrecque MP, et al. Among authors: nelson ps. J Clin Invest. 2019 Jul 30;129(10):4492-4505. doi: 10.1172/JCI128212. J Clin Invest. 2019. PMID: 31361600 Free PMC article.
Metastatic castration-resistant prostate cancer (mCRPC) is a heterogeneous disease with diverse drivers of disease progression and mechanisms of therapeutic resistance. ...
Metastatic castration-resistant prostate cancer (mCRPC) is a heterogeneous disease with diverse drivers of disease progression …
Supraphysiological androgens suppress prostate cancer growth through androgen receptor-mediated DNA damage.
Chatterjee P, Schweizer MT, Lucas JM, Coleman I, Nyquist MD, Frank SB, Tharakan R, Mostaghel E, Luo J, Pritchard CC, Lam HM, Corey E, Antonarakis ES, Denmeade SR, Nelson PS. Chatterjee P, et al. Among authors: nelson ps. J Clin Invest. 2019 Jul 16;129(10):4245-4260. doi: 10.1172/JCI127613. J Clin Invest. 2019. PMID: 31310591 Free PMC article.
Prostate cancer (PC) is initially dependent on androgen receptor (AR) signaling for survival and growth. ...
Prostate cancer (PC) is initially dependent on androgen receptor (AR) signaling for survival and growth. ...
Durable Response of Enzalutamide-resistant Prostate Cancer to Supraphysiological Testosterone Is Associated with a Multifaceted Growth Suppression and Impaired DNA Damage Response Transcriptomic Program in Patient-derived Xenografts.
Lam HM, Nguyen HM, Labrecque MP, Brown LG, Coleman IM, Gulati R, Lakely B, Sondheim D, Chatterjee P, Marck BT, Matsumoto AM, Mostaghel EA, Schweizer MT, Nelson PS, Corey E. Lam HM, et al. Among authors: nelson ps. Eur Urol. 2020 Feb;77(2):144-155. doi: 10.1016/j.eururo.2019.05.042. Epub 2019 Jun 19. Eur Urol. 2020. PMID: 31227306 Free PMC article.
BACKGROUND: Androgen deprivation therapy improves the survival of castration-resistant prostate cancer (CRPC) patients, yet ultimately fails with debilitating side effects. Supraphysiological testosterone (SPT)-based therapy produces clinical responses with improved …
BACKGROUND: Androgen deprivation therapy improves the survival of castration-resistant prostate cancer (CRPC) patients, yet ul …
Establishing a cryopreservation protocol for patient-derived xenografts of prostate cancer.
Porter LH, Lawrence MG, Wang H, Clark AK, Bakshi A, Obinata D, Goode D, Papargiris M, Mural, Clouston D, Ryan A, Norden S, Corey E, Nelson PS, Isaacs JT, Grummet J, Kourambas J, Sandhu S, Murphy DG, Pook D, Frydenberg M, Taylor RA, Risbridger GP. Porter LH, et al. Among authors: nelson ps. Prostate. 2019 Aug;79(11):1326-1337. doi: 10.1002/pros.23839. Epub 2019 Jun 18. Prostate. 2019. PMID: 31212368
As these models are challenging to establish from prostate cancer specimens, the ability to preserve them through cryopreservation has several advantages for ongoing research. Despite this, there is still uncertainty about the ability to cryopreserve PDXs of pros …
As these models are challenging to establish from prostate cancer specimens, the ability to preserve them through cryopreserva …
Targetable mechanisms driving immunoevasion of persistent senescent cells link chemotherapy-resistant cancer to aging.
Muñoz DP, Yannone SM, Daemen A, Sun Y, Vakar-Lopez F, Kawahara M, Freund AM, Rodier F, Wu JD, Desprez PY, Raulet DH, Nelson PS, van 't Veer LJ, Campisi J, Coppé JP. Muñoz DP, et al. Among authors: nelson ps. JCI Insight. 2019 Jun 11;5(14):e124716. doi: 10.1172/jci.insight.124716. JCI Insight. 2019. PMID: 31184599 Free PMC article.
Here, we identify cooperative mechanisms that orchestrate the immunoevasion and persistence of normal and cancer human SnCs through extracellular targeting of natural killer receptor signaling. ...These coordinated immunoediting processes are evident in residual, drug-resi …
Here, we identify cooperative mechanisms that orchestrate the immunoevasion and persistence of normal and cancer human SnCs through e …
Publisher Correction: The long tail of oncogenic drivers in prostate cancer.
Armenia J, Wankowicz SAM, Liu D, Gao J, Kundra R, Reznik E, Chatila WK, Chakravarty D, Han GC, Coleman I, Montgomery B, Pritchard C, Morrissey C, Barbieri CE, Beltran H, Sboner A, Zafeiriou Z, Miranda S, Bielski CM, Penson AV, Tolonen C, Huang FW, Robinson D, Wu YM, Lonigro R, Garraway LA, Demichelis F, Kantoff PW, Taplin ME, Abida W, Taylor BS, Scher HI, Nelson PS, de Bono JS, Rubin MA, Sawyers CL, Chinnaiyan AM; PCF/SU2C International Prostate Cancer Dream Team; Schultz N, Van Allen EM. Armenia J, et al. Among authors: nelson ps. Nat Genet. 2019 Jul;51(7):1194. doi: 10.1038/s41588-019-0451-6. Nat Genet. 2019. PMID: 31152158
Genomic distinctions between metastatic lower and upper tract urothelial carcinoma revealed through rapid autopsy.
Winters BR, De Sarkar N, Arora S, Bolouri H, Jana S, Vakar-Lopez F, Cheng HH, Schweizer MT, Yu EY, Grivas P, Lee JK, Kollath L, Holt SK, McFerrin L, Ha G, Nelson PS, Montgomery RB, Wright JL, Lam HM, Hsieh AC. Winters BR, et al. Among authors: nelson ps. JCI Insight. 2019 May 30;5(13):e128728. doi: 10.1172/jci.insight.128728. JCI Insight. 2019. PMID: 31145100 Free PMC article.
Our data also indicate that metastatic UTUC lesions can arise from small clonal populations present in the primary cancer. Importantly, putative druggable mutations were found across patients with the majority shared across all metastases within a patient. ...
Our data also indicate that metastatic UTUC lesions can arise from small clonal populations present in the primary cancer. Importantl …
Genomic Characterization of Prostatic Ductal Adenocarcinoma Identifies a High Prevalence of DNA Repair Gene Mutations.
Schweizer MT, Antonarakis ES, Bismar TA, Guedes LB, Cheng HH, Tretiakova MS, Vakar-Lopez F, Klemfuss N, Konnick EQ, Mostaghel EA, Hsieh AC, Nelson PS, Yu EY, Montgomery RB, True LD, Epstein JI, Lotan TL, Pritchard CC. Schweizer MT, et al. Among authors: nelson ps. JCO Precis Oncol. 2019;3:PO.18.00327. doi: 10.1200/PO.18.00327. Epub 2019 Apr 18. JCO Precis Oncol. 2019. PMID: 31123724 Free PMC article.
PURPOSE: Ductal prostate cancer (dPC) is a rare variant of prostatic adenocarcinoma associated with poor outcomes. ...Case series 1 included men who were prospectively enrolled in a tumor sequencing study at the University of Washington ( …
PURPOSE: Ductal prostate cancer (dPC) is a rare variant of prostatic adenocarcinoma associated with poor outcomes. ...C …
Upregulation of Scavenger Receptor B1 Is Required for Steroidogenic and Nonsteroidogenic Cholesterol Metabolism in Prostate Cancer.
Gordon JA, Noble JW, Midha A, Derakhshan F, Wang G, Adomat HH, Tomlinson Guns ES, Lin YY, Ren S, Collins CC, Nelson PS, Morrissey C, Wasan KM, Cox ME. Gordon JA, et al. Among authors: nelson ps. Cancer Res. 2019 Jul 1;79(13):3320-3331. doi: 10.1158/0008-5472.CAN-18-2529. Epub 2019 May 7. Cancer Res. 2019. PMID: 31064850 Free PMC article.
Aberrant cholesterol metabolism is increasingly appreciated to be essential for prostate cancer initiation and progression. Transcript expression of the high-density lipoprotein-cholesterol receptor scavenger receptor B1 (SR-B1) is elevated in primary prostate …
Aberrant cholesterol metabolism is increasingly appreciated to be essential for prostate cancer initiation and progression. Tr …
Genomic correlates of clinical outcome in advanced prostate cancer.
Abida W, Cyrta J, Heller G, Prandi D, Armenia J, Coleman I, Cieslik M, Benelli M, Robinson D, Van Allen EM, Sboner A, Fedrizzi T, Mosquera JM, Robinson BD, De Sarkar N, Kunju LP, Tomlins S, Wu YM, Nava Rodrigues D, Loda M, Gopalan A, Reuter VE, Pritchard CC, Mateo J, Bianchini D, Miranda S, Carreira S, Rescigno P, Filipenko J, Vinson J, Montgomery RB, Beltran H, Heath EI, Scher HI, Kantoff PW, Taplin ME, Schultz N, deBono JS, Demichelis F, Nelson PS, Rubin MA, Chinnaiyan AM, Sawyers CL. Abida W, et al. Among authors: nelson ps. Proc Natl Acad Sci U S A. 2019 Jun 4;116(23):11428-11436. doi: 10.1073/pnas.1902651116. Epub 2019 May 6. Proc Natl Acad Sci U S A. 2019. PMID: 31061129 Free PMC article.
Heterogeneity in the genomic landscape of metastatic prostate cancer has become apparent through several comprehensive profiling efforts, but little is known about the impact of this heterogeneity on clinical outcome. Here, we report comprehensive genomic and transc …
Heterogeneity in the genomic landscape of metastatic prostate cancer has become apparent through several comprehensive profili …
Spatially Restricted Stromal Wnt Signaling Restrains Prostate Epithelial Progenitor Growth through Direct and Indirect Mechanisms.
Wei X, Zhang L, Zhou Z, Kwon OJ, Zhang Y, Nguyen H, Dumpit R, True L, Nelson P, Dong B, Xue W, Birchmeier W, Taketo MM, Xu F, Creighton CJ, Ittmann MM, Xin L. Wei X, et al. Among authors: nelson p. Cell Stem Cell. 2019 May 2;24(5):753-768.e6. doi: 10.1016/j.stem.2019.03.010. Epub 2019 Apr 11. Cell Stem Cell. 2019. PMID: 30982770 Free PMC article.
Here, we show that stromal cells in the proximal prostatic duct near the urethra, a mouse prostate stem cell niche, not only produce multiple Wnt ligands but also exhibit strong Wnt/beta-catenin activity. ...Collectively, these pathways restrain the proliferative po …
Here, we show that stromal cells in the proximal prostatic duct near the urethra, a mouse prostate stem cell niche, not only p …
Activation of MAPK Signaling by CXCR7 Leads to Enzalutamide Resistance in Prostate Cancer.
Li S, Fong KW, Gritsina G, Zhang A, Zhao JC, Kim J, Sharp A, Yuan W, Aversa C, Yang XJ, Nelson PS, Feng FY, Chinnaiyan AM, de Bono JS, Morrissey C, Rettig MB, Yu J. Li S, et al. Among authors: nelson ps. Cancer Res. 2019 May 15;79(10):2580-2592. doi: 10.1158/0008-5472.CAN-18-2812. Epub 2019 Apr 5. Cancer Res. 2019. PMID: 30952632 Free PMC article.
Castration-resistant prostate cancer (CRPC) that has developed resistance to the new-generation androgen receptor (AR) antagonist enzalutamide is a lethal disease. ...Examination of patient specimens showed that CXCR7 and pERK levels increased significantly from loc …
Castration-resistant prostate cancer (CRPC) that has developed resistance to the new-generation androgen receptor (AR) antagon …
Association of prostate cancer SLCO gene expression with Gleason grade and alterations following androgen deprivation therapy.
Alsinnawi M, Zhang A, Bianchi-Frias D, Burns J, Cho E, Zhang X, Sowalsky A, Ye H, Slee AE, True L, Porter C, Taplin ME, Balk S, Nelson PS, Montgomery RB, Mostaghel EA. Alsinnawi M, et al. Among authors: nelson ps. Prostate Cancer Prostatic Dis. 2019 Dec;22(4):560-568. doi: 10.1038/s41391-019-0141-6. Epub 2019 Mar 19. Prostate Cancer Prostatic Dis. 2019. PMID: 30890759 Free PMC article.
BACKGROUND: SLCO-encoded transporters have been associated with progression to castration-resistant prostate cancer (CRPC) after initiation of androgen deprivation therapy (ADT). Although expressed at lower levels than in CRPC tissues, SLCO-encoded transporters may …
BACKGROUND: SLCO-encoded transporters have been associated with progression to castration-resistant prostate cancer (CRPC) aft …
Clinical determinants for successful circulating tumor DNA analysis in prostate cancer.
Schweizer MT, Gulati R, Beightol M, Konnick EQ, Cheng HH, Klemfuss N, De Sarkar N, Yu EY, Montgomery RB, Nelson PS, Pritchard CC. Schweizer MT, et al. Among authors: nelson ps. Prostate. 2019 May;79(7):701-708. doi: 10.1002/pros.23778. Epub 2019 Mar 13. Prostate. 2019. PMID: 30865311 Free PMC article.
However, next generation sequencing (NGS) of cell-free DNA (cfDNA) may not be appropriate for all patients with advanced prostate cancer (PC). METHODS: Blood was obtained from advanced PC patients for plasma-based sequencing. ...We included data from 76 patients (72 …
However, next generation sequencing (NGS) of cell-free DNA (cfDNA) may not be appropriate for all patients with advanced prostate …
ARv7 Represses Tumor-Suppressor Genes in Castration-Resistant Prostate Cancer.
Cato L, de Tribolet-Hardy J, Lee I, Rottenberg JT, Coleman I, Melchers D, Houtman R, Xiao T, Li W, Uo T, Sun S, Kuznik NC, Göppert B, Ozgun F, van Royen ME, Houtsmuller AB, Vadhi R, Rao PK, Li L, Balk SP, Den RB, Trock BJ, Karnes RJ, Jenkins RB, Klein EA, Davicioni E, Gruhl FJ, Long HW, Liu XS, Cato ACB, Lack NA, Nelson PS, Plymate SR, Groner AC, Brown M. Cato L, et al. Among authors: nelson ps. Cancer Cell. 2019 Mar 18;35(3):401-413.e6. doi: 10.1016/j.ccell.2019.01.008. Epub 2019 Feb 14. Cancer Cell. 2019. PMID: 30773341 Free PMC article.
Androgen deprivation therapy for prostate cancer (PCa) benefits patients with early disease, but becomes ineffective as PCa progresses to a castration-resistant state (CRPC). ...
Androgen deprivation therapy for prostate cancer (PCa) benefits patients with early disease, but becomes ineffective as PCa pr …
EZH2 cooperates with gain-of-function p53 mutants to promote cancer growth and metastasis.
Zhao Y, Ding L, Wang D, Ye Z, He Y, Ma L, Zhu R, Pan Y, Wu Q, Pang K, Hou X, Weroha SJ, Han C, Coleman R, Coleman I, Karnes RJ, Zhang J, Nelson PS, Wang L, Huang H. Zhao Y, et al. Among authors: nelson ps. EMBO J. 2019 Mar 1;38(5):e99599. doi: 10.15252/embj.201899599. Epub 2019 Feb 5. EMBO J. 2019. PMID: 30723117 Free PMC article.
EZH2 augmented p53 GOF mutant-mediated cancer growth and metastasis by increasing protein levels of mutant p53. EZH2 overexpression was associated with worsened outcome selectively in patients with p53-mutated cancer. Depletion of EZH2 by antisense oligonucleotides …
EZH2 augmented p53 GOF mutant-mediated cancer growth and metastasis by increasing protein levels of mutant p53. EZH2 overexpression w …
Targeting the perivascular niche sensitizes disseminated tumour cells to chemotherapy.
Carlson P, Dasgupta A, Grzelak CA, Kim J, Barrett A, Coleman IM, Shor RE, Goddard ET, Dai J, Schweitzer EM, Lim AR, Crist SB, Cheresh DA, Nelson PS, Hansen KC, Ghajar CM. Carlson P, et al. Among authors: nelson ps. Nat Cell Biol. 2019 Feb;21(2):238-250. doi: 10.1038/s41556-018-0267-0. Epub 2019 Jan 21. Nat Cell Biol. 2019. PMID: 30664790 Free PMC article.
The presence of disseminated tumour cells (DTCs) in bone marrow is predictive of poor metastasis-free survival of patients with breast cancer with localized disease. DTCs persist in distant tissues despite systemic administration of adjuvant chemotherapy. ...
The presence of disseminated tumour cells (DTCs) in bone marrow is predictive of poor metastasis-free survival of patients with breast ca …
Performance of PCA3 and TMPRSS2:ERG urinary biomarkers in prediction of biopsy outcome in the Canary Prostate Active Surveillance Study (PASS).
Newcomb LF, Zheng Y, Faino AV, Bianchi-Frias D, Cooperberg MR, Brown MD, Brooks JD, Dash A, Fabrizio MD, Gleave ME, Liss M, Morgan TM, Thompson IM, Wagner AA, Carroll PR, Nelson PS, Lin DW. Newcomb LF, et al. Among authors: nelson ps. Prostate Cancer Prostatic Dis. 2019 Sep;22(3):438-445. doi: 10.1038/s41391-018-0124-z. Epub 2019 Jan 21. Prostate Cancer Prostatic Dis. 2019. PMID: 30664734 Free PMC article.
BACKGROUND: For men on active surveillance for prostate cancer, biomarkers may improve prediction of reclassification to higher grade or volume cancer. ...RESULTS: Seven hundred and eighty-two men contributed 2069 urine specimens. After adjusting for PSA, …
BACKGROUND: For men on active surveillance for prostate cancer, biomarkers may improve prediction of reclassification to highe …
ONECUT2 is a targetable master regulator of lethal prostate cancer that suppresses the androgen axis.
Rotinen M, You S, Yang J, Coetzee SG, Reis-Sobreiro M, Huang WC, Huang F, Pan X, Yáñez A, Hazelett DJ, Chu CY, Steadman K, Morrissey CM, Nelson PS, Corey E, Chung LWK, Freedland SJ, Di Vizio D, Garraway IP, Murali R, Knudsen BS, Freeman MR. Rotinen M, et al. Among authors: nelson ps. Nat Med. 2018 Dec;24(12):1887-1898. doi: 10.1038/s41591-018-0241-1. Epub 2018 Nov 26. Nat Med. 2018. PMID: 30478421 Free PMC article.
Treatment of prostate cancer (PC) by androgen suppression promotes the emergence of aggressive variants that are androgen receptor (AR) independent. Here we identify the transcription factor ONECUT2 (OC2) as a master regulator of AR networks in metastatic castration …
Treatment of prostate cancer (PC) by androgen suppression promotes the emergence of aggressive variants that are androgen rece …
Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer.
Rodrigues DN, Rescigno P, Liu D, Yuan W, Carreira S, Lambros MB, Seed G, Mateo J, Riisnaes R, Mullane S, Margolis C, Miao D, Miranda S, Dolling D, Clarke M, Bertan C, Crespo M, Boysen G, Ferreira A, Sharp A, Figueiredo I, Keliher D, Aldubayan S, Burke KP, Sumanasuriya S, Fontes MS, Bianchini D, Zafeiriou Z, Mendes LST, Mouw K, Schweizer MT, Pritchard CC, Salipante S, Taplin ME, Beltran H, Rubin MA, Cieslik M, Robinson D, Heath E, Schultz N, Armenia J, Abida W, Scher H, Lord C, D'Andrea A, Sawyers CL, Chinnaiyan AM, Alimonti A, Nelson PS, Drake CG, Van Allen EM, de Bono JS. Rodrigues DN, et al. Among authors: nelson ps. J Clin Invest. 2018 Nov 1;128(11):5185. doi: 10.1172/JCI125184. Epub 2018 Nov 1. J Clin Invest. 2018. PMID: 30382943 Free PMC article. No abstract available.
DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGS.
Trachtman H, Nelson P, Adler S, Campbell KN, Chaudhuri A, Derebail VK, Gambaro G, Gesualdo L, Gipson DS, Hogan J, Lieberman K, Marder B, Meyers KE, Mustafa E, Radhakrishnan J, Srivastava T, Stepanians M, Tesar V, Zhdanova O, Komers R; DUET Study Group. Trachtman H, et al. Among authors: nelson p. J Am Soc Nephrol. 2018 Nov;29(11):2745-2754. doi: 10.1681/ASN.2018010091. J Am Soc Nephrol. 2018. PMID: 30361325 Free PMC article. Clinical Trial.
Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer.
Sharp A, Coleman I, Yuan W, Sprenger C, Dolling D, Rodrigues DN, Russo JW, Figueiredo I, Bertan C, Seed G, Riisnaes R, Uo T, Neeb A, Welti J, Morrissey C, Carreira S, Luo J, Nelson PS, Balk SP, True LD, de Bono JS, Plymate SR. Sharp A, et al. Among authors: nelson ps. J Clin Invest. 2019 Jan 2;129(1):192-208. doi: 10.1172/JCI122819. Epub 2018 Nov 26. J Clin Invest. 2019. PMID: 30334814 Free PMC article.
CONCLUSION: This study provides impetus to develop therapies that abrogate AR-V7 signaling to improve our understanding of AR-V7 biology and to confirm the clinical significance of AR-V7. FUNDING: Work at the University of Washington and in the Plymate and Ne …
CONCLUSION: This study provides impetus to develop therapies that abrogate AR-V7 signaling to improve our understanding of AR-V7 biology and …
Downregulation of Dipeptidyl Peptidase 4 Accelerates Progression to Castration-Resistant Prostate Cancer.
Russo JW, Gao C, Bhasin SS, Voznesensky OS, Calagua C, Arai S, Nelson PS, Montgomery B, Mostaghel EA, Corey E, Taplin ME, Ye H, Bhasin M, Balk SP. Russo JW, et al. Among authors: nelson ps. Cancer Res. 2018 Nov 15;78(22):6354-6362. doi: 10.1158/0008-5472.CAN-18-0687. Epub 2018 Sep 21. Cancer Res. 2018. PMID: 30242112 Free PMC article.
The standard treatment for metastatic prostate cancer, androgen deprivation therapy (ADT), is designed to suppress androgen receptor (AR) activity. However, men invariably progress to castration-resistant prostate cancer (CRPC), and AR reactivation con …
The standard treatment for metastatic prostate cancer, androgen deprivation therapy (ADT), is designed to suppress androgen re …
The Aged Microenvironment Influences the Tumorigenic Potential of Malignant Prostate Epithelial Cells.
Bianchi-Frias D, Damodarasamy M, Hernandez SA, Gil da Costa RM, Vakar-Lopez F, Coleman IM, Reed MJ, Nelson PS. Bianchi-Frias D, et al. Among authors: nelson ps. Mol Cancer Res. 2019 Jan;17(1):321-331. doi: 10.1158/1541-7786.MCR-18-0522. Epub 2018 Sep 17. Mol Cancer Res. 2019. PMID: 30224545 Free article.
The incidence of prostate cancer is directly linked to age, but age-associated changes that facilitate prostate cancer development and progression are poorly understood. This study investigated age-related changes in the prostate microenvironmen …
The incidence of prostate cancer is directly linked to age, but age-associated changes that facilitate prostate canc …
Contribution of Adrenal Glands to Intratumor Androgens and Growth of Castration-Resistant Prostate Cancer.
Mostaghel EA, Zhang A, Hernandez S, Marck BT, Zhang X, Tamae D, Biehl HE, Tretiakova M, Bartlett J, Burns J, Dumpit R, Ang L, Matsumoto AM, Penning TM, Balk SP, Morrissey C, Corey E, True LD, Nelson PS. Mostaghel EA, et al. Among authors: nelson ps. Clin Cancer Res. 2019 Jan 1;25(1):426-439. doi: 10.1158/1078-0432.CCR-18-1431. Epub 2018 Sep 4. Clin Cancer Res. 2019. PMID: 30181386 Free PMC article.
PURPOSE: Tumor androgens in castration-resistant prostate cancer (CRPC) reflect de novo intratumoral synthesis or adrenal androgens. We used C.B.-17 SCID mice in which we observed adrenal CYP17A activity to isolate the impact of adrenal steroids on CRPC tumors in vi …
PURPOSE: Tumor androgens in castration-resistant prostate cancer (CRPC) reflect de novo intratumoral synthesis or adrenal andr …
Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer.
Nava Rodrigues D, Rescigno P, Liu D, Yuan W, Carreira S, Lambros MB, Seed G, Mateo J, Riisnaes R, Mullane S, Margolis C, Miao D, Miranda S, Dolling D, Clarke M, Bertan C, Crespo M, Boysen G, Ferreira A, Sharp A, Figueiredo I, Keliher D, Aldubayan S, Burke KP, Sumanasuriya S, Fontes MS, Bianchini D, Zafeiriou Z, Teixeira Mendes LS, Mouw K, Schweizer MT, Pritchard CC, Salipante S, Taplin ME, Beltran H, Rubin MA, Cieslik M, Robinson D, Heath E, Schultz N, Armenia J, Abida W, Scher H, Lord C, D'Andrea A, Sawyers CL, Chinnaiyan AM, Alimonti A, Nelson PS, Drake CG, Van Allen EM, de Bono JS. Nava Rodrigues D, et al. Among authors: nelson ps. J Clin Invest. 2018 Oct 1;128(10):4441-4453. doi: 10.1172/JCI121924. Epub 2018 Sep 4. J Clin Invest. 2018. PMID: 30179225 Free PMC article. Clinical Trial.
BACKGROUND: Understanding the integrated immunogenomic landscape of advanced prostate cancer (APC) could impact stratified treatment selection. METHODS: Defective mismatch repair (dMMR) status was determined by either loss of mismatch repair protein expression on IH …
BACKGROUND: Understanding the integrated immunogenomic landscape of advanced prostate cancer (APC) could impact stratified tre …
Recent advances in prostate cancer research: large-scale genomic analyses reveal novel driver mutations and DNA repair defects.
Frank S, Nelson P, Vasioukhin V. Frank S, et al. Among authors: nelson p. F1000Res. 2018 Aug 2;7:F1000 Faculty Rev-1173. doi: 10.12688/f1000research.14499.1. eCollection 2018. F1000Res. 2018. PMID: 30135717 Free PMC article. Review.
Prostate cancer (PCa) is a disease of mutated and misregulated genes. However, primary prostate tumors have relatively few mutations, and only three genes ( ERG, PTEN, and SPOP) are recurrently mutated in more than 10% of primary tumors. ...Overall, instead o …
Prostate cancer (PCa) is a disease of mutated and misregulated genes. However, primary prostate tumors have relatively …
Continued 5alpha-Reductase Inhibitor Use after Prostate Cancer Diagnosis and the Risk of Reclassification and Adverse Pathological Outcomes in the PASS.
Kearns JT, Faino AV, Schenk JM, Newcomb LF, Brooks JD, Carroll PR, Dash A, Ellis WJ, Fabrizio M, Gleave ME, Morgan TM, Nelson PS, Thompson IM, Wagner A, Zheng Y, Lin DW. Kearns JT, et al. Among authors: nelson ps. J Urol. 2019 Jan;201(1):106-111. doi: 10.1016/j.juro.2018.07.065. J Urol. 2019. PMID: 30076904 Free PMC article.
PURPOSE: Outcomes in patients who enroll in active surveillance programs for prostate cancer while receiving 5alpha-reductase inhibitors have not been well defined. ...CONCLUSIONS: Continued 5alpha-reductase inhibitor use after an initial diagnosis of prostate …
PURPOSE: Outcomes in patients who enroll in active surveillance programs for prostate cancer while receiving 5alpha-reductase …
A Novel Flavonoid Composition Targets Androgen Receptor Signaling and Inhibits Prostate Cancer Growth in Preclinical Models.
Mamouni K, Zhang S, Li X, Chen Y, Yang Y, Kim J, Bartlett MG, Coleman IM, Nelson PS, Kucuk O, Wu D. Mamouni K, et al. Among authors: nelson ps. Neoplasia. 2018 Aug;20(8):789-799. doi: 10.1016/j.neo.2018.06.003. Epub 2018 Jul 4. Neoplasia. 2018. PMID: 29981500 Free PMC article.
The high prevalence and long latency period of prostate cancer (PCa) provide a unique opportunity to control disease progression with dietary and nutraceutical approaches. ...
The high prevalence and long latency period of prostate cancer (PCa) provide a unique opportunity to control disease progressi …
Neoadjuvant-Intensive Androgen Deprivation Therapy Selects for Prostate Tumor Foci with Diverse Subclonal Oncogenic Alterations.
Sowalsky AG, Ye H, Bhasin M, Van Allen EM, Loda M, Lis RT, Montaser-Kouhsari L, Calagua C, Ma F, Russo JW, Schaefer RJ, Voznesensky OS, Zhang Z, Bubley GJ, Montgomery B, Mostaghel EA, Nelson PS, Taplin ME, Balk SP. Sowalsky AG, et al. Among authors: nelson ps. Cancer Res. 2018 Aug 15;78(16):4716-4730. doi: 10.1158/0008-5472.CAN-18-0610. Epub 2018 Jun 19. Cancer Res. 2018. PMID: 29921690 Free PMC article.
Primary prostate cancer can have extensive microheterogeneity, but its contribution to the later emergence of metastatic castration-resistant prostate cancer (mCRPC) remains unclear. ...Comprehensive molecular analyses of primary prostate can …
Primary prostate cancer can have extensive microheterogeneity, but its contribution to the later emergence of metastatic castr …
Structural Alterations Driving Castration-Resistant Prostate Cancer Revealed by Linked-Read Genome Sequencing.
Viswanathan SR, Ha G, Hoff AM, Wala JA, Carrot-Zhang J, Whelan CW, Haradhvala NJ, Freeman SS, Reed SC, Rhoades J, Polak P, Cipicchio M, Wankowicz SA, Wong A, Kamath T, Zhang Z, Gydush GJ, Rotem D; PCF/SU2C International Prostate Cancer Dream Team; Love JC, Getz G, Gabriel S, Zhang CZ, Dehm SM, Nelson PS, Van Allen EM, Choudhury AD, Adalsteinsson VA, Beroukhim R, Taplin ME, Meyerson M. Viswanathan SR, et al. Among authors: nelson ps. Cell. 2018 Jul 12;174(2):433-447.e19. doi: 10.1016/j.cell.2018.05.036. Epub 2018 Jun 18. Cell. 2018. PMID: 29909985 Free PMC article.
Nearly all prostate cancer deaths are from metastatic castration-resistant prostate cancer (mCRPC), but there have been few whole-genome sequencing (WGS) studies of this disease state. ...In addition to frequent rearrangements affecting known prosta …
Nearly all prostate cancer deaths are from metastatic castration-resistant prostate cancer (mCRPC), but there ha …
Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer.
Wu YM, Cieślik M, Lonigro RJ, Vats P, Reimers MA, Cao X, Ning Y, Wang L, Kunju LP, de Sarkar N, Heath EI, Chou J, Feng FY, Nelson PS, de Bono JS, Zou W, Montgomery B, Alva A; PCF/SU2C International Prostate Cancer Dream Team; Robinson DR, Chinnaiyan AM. Wu YM, et al. Among authors: nelson ps. Cell. 2018 Jun 14;173(7):1770-1782.e14. doi: 10.1016/j.cell.2018.04.034. Cell. 2018. PMID: 29906450 Free PMC article.
Using integrative genomic analysis of 360 metastatic castration-resistant prostate cancer (mCRPC) samples, we identified a novel subtype of prostate cancer typified by biallelic loss of CDK12 that is mutually exclusive with tumors driven by DNA repair …
Using integrative genomic analysis of 360 metastatic castration-resistant prostate cancer (mCRPC) samples, we identified a nov …
A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer.
Schweizer MT, Haugk K, McKiernan JS, Gulati R, Cheng HH, Maes JL, Dumpit RF, Nelson PS, Montgomery B, McCune JS, Plymate SR, Yu EY. Schweizer MT, et al. Among authors: nelson ps. PLoS One. 2018 Jun 1;13(6):e0198389. doi: 10.1371/journal.pone.0198389. eCollection 2018. PLoS One. 2018. PMID: 29856824 Free PMC article. Clinical Trial.
BACKGROUND: Niclosamide, an FDA-approved anti-helminthic drug, has activity in preclinical models of castration-resistant prostate cancer (CRPC). Potential mechanisms of action include degrading constitutively active androgen receptor splice variants (AR-Vs) or inhi …
BACKGROUND: Niclosamide, an FDA-approved anti-helminthic drug, has activity in preclinical models of castration-resistant prostate …
Microsatellite instability in prostate cancer by PCR or next-generation sequencing.
Hempelmann JA, Lockwood CM, Konnick EQ, Schweizer MT, Antonarakis ES, Lotan TL, Montgomery B, Nelson PS, Klemfuss N, Salipante SJ, Pritchard CC. Hempelmann JA, et al. Among authors: nelson ps. J Immunother Cancer. 2018 Apr 17;6(1):29. doi: 10.1186/s40425-018-0341-y. J Immunother Cancer. 2018. PMID: 29665853 Free PMC article.
BACKGROUND: Microsatellite instability (MSI) is now being used as a sole biomarker to guide immunotherapy treatment for men with advanced prostate cancer. Yet current molecular diagnostic tests for MSI have not been evaluated for use in prostate cancer …
BACKGROUND: Microsatellite instability (MSI) is now being used as a sole biomarker to guide immunotherapy treatment for men with advanced …
The long tail of oncogenic drivers in prostate cancer.
Armenia J, Wankowicz SAM, Liu D, Gao J, Kundra R, Reznik E, Chatila WK, Chakravarty D, Han GC, Coleman I, Montgomery B, Pritchard C, Morrissey C, Barbieri CE, Beltran H, Sboner A, Zafeiriou Z, Miranda S, Bielski CM, Penson AV, Tolonen C, Huang FW, Robinson D, Wu YM, Lonigro R, Garraway LA, Demichelis F, Kantoff PW, Taplin ME, Abida W, Taylor BS, Scher HI, Nelson PS, de Bono JS, Rubin MA, Sawyers CL, Chinnaiyan AM; PCF/SU2C International Prostate Cancer Dream Team; Schultz N, Van Allen EM. Armenia J, et al. Among authors: nelson ps. Nat Genet. 2018 May;50(5):645-651. doi: 10.1038/s41588-018-0078-z. Epub 2018 Apr 2. Nat Genet. 2018. PMID: 29610475 Free PMC article.
Comprehensive genomic characterization of prostate cancer has identified recurrent alterations in genes involved in androgen signaling, DNA repair, and PI3K signaling, among others. ...We identify a total of 97 SMGs, including 70 not previously implicated in pros …
Comprehensive genomic characterization of prostate cancer has identified recurrent alterations in genes involved in androgen s …
Boolean analysis identifies CD38 as a biomarker of aggressive localized prostate cancer.
Sahoo D, Wei W, Auman H, Hurtado-Coll A, Carroll PR, Fazli L, Gleave ME, Lin DW, Nelson PS, Simko J, Thompson IM, Leach RJ, Troyer DA, True LD, McKenney JK, Feng Z, Brooks JD. Sahoo D, et al. Among authors: nelson ps. Oncotarget. 2018 Jan 5;9(5):6550-6561. doi: 10.18632/oncotarget.23973. eCollection 2018 Jan 19. Oncotarget. 2018. PMID: 29464091 Free PMC article.
The introduction of serum Prostate Specific Antigen (PSA) testing nearly 30 years ago has been associated with a significant shift towards localized disease and decreased deaths due to prostate cancer. ...Recent studies show that cancer is heterogeneou …
The introduction of serum Prostate Specific Antigen (PSA) testing nearly 30 years ago has been associated with a significant shift to …
Refined Analysis of Prostate-specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance Outcomes.
Cooperberg MR, Brooks JD, Faino AV, Newcomb LF, Kearns JT, Carroll PR, Dash A, Etzioni R, Fabrizio MD, Gleave ME, Morgan TM, Nelson PS, Thompson IM, Wagner AA, Lin DW, Zheng Y. Cooperberg MR, et al. Among authors: nelson ps. Eur Urol. 2018 Aug;74(2):211-217. doi: 10.1016/j.eururo.2018.01.017. Epub 2018 Feb 9. Eur Urol. 2018. PMID: 29433975 Free PMC article.
BACKGROUND: For men on active surveillance for prostate cancer, utility of prostate-specific antigen (PSA) kinetics (PSAk) in predicting pathologic reclassification remains controversial. ...PATIENT SUMMARY: In this report, we looked at whether repeat pros …
BACKGROUND: For men on active surveillance for prostate cancer, utility of prostate-specific antigen (PSA) kinetics (PS …
Role of Surveillance Biopsy with No Cancer as a Prognostic Marker for Reclassification: Results from the Canary Prostate Active Surveillance Study.
Kearns JT, Faino AV, Newcomb LF, Brooks JD, Carroll PR, Dash A, Ellis WJ, Fabrizio M, Gleave ME, Morgan TM, Nelson PS, Thompson IM, Wagner AA, Zheng Y, Lin DW. Kearns JT, et al. Among authors: nelson ps. Eur Urol. 2018 May;73(5):706-712. doi: 10.1016/j.eururo.2018.01.016. Epub 2018 Feb 9. Eur Urol. 2018. PMID: 29433973 Free PMC article.
BACKGROUND: Many patients who are on active surveillance (AS) for prostate cancer will have surveillance prostate needle biopsies (PNBs) without any cancer evident. ...PATIENT SUMMARY: Men on active surveillance for prostate cancer who ha …
BACKGROUND: Many patients who are on active surveillance (AS) for prostate cancer will have surveillance prostate needl …
Clinical Outcome of Prostate Cancer Patients with Germline DNA Repair Mutations: Retrospective Analysis from an International Study.
Mateo J, Cheng HH, Beltran H, Dolling D, Xu W, Pritchard CC, Mossop H, Rescigno P, Perez-Lopez R, Sailer V, Kolinsky M, Balasopoulou A, Bertan C, Nanus DM, Tagawa ST, Thorne H, Montgomery B, Carreira S, Sandhu S, Rubin MA, Nelson PS, de Bono JS. Mateo J, et al. Among authors: nelson ps. Eur Urol. 2018 May;73(5):687-693. doi: 10.1016/j.eururo.2018.01.010. Epub 2018 Feb 8. Eur Urol. 2018. PMID: 29429804 Free PMC article.
BACKGROUND: Germline DNA damage repair gene mutation (gDDRm) is found in >10% of metastatic prostate cancer (mPC). Their prognostic and predictive impact relating to standard therapies is unclear. ...PATIENT SUMMARY: Patients with inherited DNA repair mutations b …
BACKGROUND: Germline DNA damage repair gene mutation (gDDRm) is found in >10% of metastatic prostate cancer (mPC). Their pr …
Prostate Cancer Disseminated Tumor Cells are Rarely Detected in the Bone Marrow of Patients with Localized Disease Undergoing Radical Prostatectomy across Multiple Rare Cell Detection Platforms.
Chalfin HJ, Glavaris SA, Malihi PD, Sperger JM, Gorin MA, Lu C, Goodwin CR, Chen Y, Caruso EA, Dumpit R, Kuhn P, Lang JM, Nelson PS, Luo J, Pienta KJ. Chalfin HJ, et al. Among authors: nelson ps. J Urol. 2018 Jun;199(6):1494-1501. doi: 10.1016/j.juro.2018.01.033. Epub 2018 Jan 12. J Urol. 2018. PMID: 29339080 Free PMC article.
PURPOSE: Prostate circulating tumor cells escape into peripheral blood and enter bone marrow as disseminated tumor cells, representing an early step before conventionally detectable metastasis. ...CONCLUSIONS: Evaluation across multiple platforms revealed that epithelial m …
PURPOSE: Prostate circulating tumor cells escape into peripheral blood and enter bone marrow as disseminated tumor cells, representin …
A Phase 2, Double-Blind, Placebo-Controlled, Randomized Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis.
Vincenti F, Fervenza FC, Campbell KN, Diaz M, Gesualdo L, Nelson P, Praga M, Radhakrishnan J, Sellin L, Singh A, Thornley-Brown D, Veronese FV, Accomando B, Engstrand S, Ledbetter S, Lin J, Neylan J, Tumlin J; Focal Segmental Glomerulosclerosis Study Group. Vincenti F, et al. Among authors: nelson p. Kidney Int Rep. 2017 Apr 7;2(5):800-810. doi: 10.1016/j.ekir.2017.03.011. eCollection 2017 Sep. Kidney Int Rep. 2017. PMID: 29270487 Free PMC article.
Post prostatectomy outcomes of patients with high-risk prostate cancer treated with neoadjuvant androgen blockade.
McKay RR, Montgomery B, Xie W, Zhang Z, Bubley GJ, Lin DW, Preston MA, Trinh QD, Chang P, Wagner AA, Mostaghel EA, Kantoff PW, Nelson PS, Kibel AS, Taplin ME. McKay RR, et al. Among authors: nelson ps. Prostate Cancer Prostatic Dis. 2018 Sep;21(3):364-372. doi: 10.1038/s41391-017-0009-6. Epub 2017 Dec 20. Prostate Cancer Prostatic Dis. 2018. PMID: 29263420 Free PMC article.
BACKGROUND: Patients with high-risk prostate cancer have an increased likelihood of experiencing a relapse following radical prostatectomy (RP). ...
BACKGROUND: Patients with high-risk prostate cancer have an increased likelihood of experiencing a relapse following radical p …
Supraphysiologic Testosterone Therapy in the Treatment of Prostate Cancer: Models, Mechanisms and Questions.
Mohammad OS, Nyquist MD, Schweizer MT, Balk SP, Corey E, Plymate S, Nelson PS, Mostaghel EA. Mohammad OS, et al. Among authors: nelson ps. Cancers (Basel). 2017 Dec 6;9(12):166. doi: 10.3390/cancers9120166. Cancers (Basel). 2017. PMID: 29210989 Free PMC article. Review.
Since Huggins defined the androgen-sensitive nature of prostate cancer (PCa), suppression of systemic testosterone (T) has remained the most effective initial therapy for advanced disease although progression inevitably occurs. From the inception of clinical efforts …
Since Huggins defined the androgen-sensitive nature of prostate cancer (PCa), suppression of systemic testosterone (T) has rem …
Efficacy and Safety of Sparsentan Compared With Irbesartan in Patients With Primary Focal Segmental Glomerulosclerosis: Randomized, Controlled Trial Design (DUET).
Komers R, Gipson DS, Nelson P, Adler S, Srivastava T, Derebail VK, Meyers KE, Pergola P, MacNally ME, Hunt JL, Shih A, Trachtman H. Komers R, et al. Among authors: nelson p. Kidney Int Rep. 2017 Mar 4;2(4):654-664. doi: 10.1016/j.ekir.2017.02.019. eCollection 2017 Jul. Kidney Int Rep. 2017. PMID: 29142983 Free PMC article.
PTEN loss is associated with prostate cancer recurrence and alterations in tumor DNA methylation profiles.
Geybels MS, Fang M, Wright JL, Qu X, Bibikova M, Klotzle B, Fan JB, Feng Z, Ostrander EA, Nelson PS, Stanford JL. Geybels MS, et al. Among authors: nelson ps. Oncotarget. 2017 Sep 15;8(48):84338-84348. doi: 10.18632/oncotarget.20940. eCollection 2017 Oct 13. Oncotarget. 2017. PMID: 29137428 Free PMC article.
BACKGROUND: Prostate cancer (PCa) with loss of the tumor suppressor gene PTEN has an unfavorable prognosis. ...CONCLUSION: Loss of PTEN was positively associated with PCa recurrence. Prostate tumors with PTEN loss harbor a distinct methylation signature, and …
BACKGROUND: Prostate cancer (PCa) with loss of the tumor suppressor gene PTEN has an unfavorable prognosis. ...CONCLUSION: Los …
Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling.
Bluemn EG, Coleman IM, Lucas JM, Coleman RT, Hernandez-Lopez S, Tharakan R, Bianchi-Frias D, Dumpit RF, Kaipainen A, Corella AN, Yang YC, Nyquist MD, Mostaghel E, Hsieh AC, Zhang X, Corey E, Brown LG, Nguyen HM, Pienta K, Ittmann M, Schweizer M, True LD, Wise D, Rennie PS, Vessella RL, Morrissey C, Nelson PS. Bluemn EG, et al. Among authors: nelson ps. Cancer Cell. 2017 Oct 9;32(4):474-489.e6. doi: 10.1016/j.ccell.2017.09.003. Cancer Cell. 2017. PMID: 29017058 Free PMC article.
Androgen receptor (AR) signaling is a distinctive feature of prostate carcinoma (PC) and represents the major therapeutic target for treating metastatic prostate cancer (mPC). ...
Androgen receptor (AR) signaling is a distinctive feature of prostate carcinoma (PC) and represents the major therapeutic target for …
Erratum: ETS Related Gene mediated Androgen Receptor Aggregation and Endoplasmic Reticulum Stress in Prostate Cancer Development.
Sreenath TL, Macalindong SS, Mikhalkevich N, Sharad S, Mohamed A, Young D, Borbiev T, Xavier C, Gupta R, Jamal M, Babcock K, Tan SH, Nevalainen MT, Dobi A, Petrovics G, Sesterhenn IA, Rosner IL, Bieberich CJ, Nelson P, Vasioukhin V, Srivastava S. Sreenath TL, et al. Among authors: nelson p. Sci Rep. 2017 Sep 6;7(1):10693. doi: 10.1038/s41598-017-09612-4. Sci Rep. 2017. PMID: 28878398 Free PMC article.
Novel Junction-specific and Quantifiable In Situ Detection of AR-V7 and its Clinical Correlates in Metastatic Castration-resistant Prostate Cancer.
Zhu Y, Sharp A, Anderson CM, Silberstein JL, Taylor M, Lu C, Zhao P, De Marzo AM, Antonarakis ES, Wang M, Wu X, Luo Y, Su N, Nava Rodrigues D, Figueiredo I, Welti J, Park E, Ma XJ, Coleman I, Morrissey C, Plymate SR, Nelson PS, de Bono JS, Luo J. Zhu Y, et al. Among authors: nelson ps. Eur Urol. 2018 May;73(5):727-735. doi: 10.1016/j.eururo.2017.08.009. Epub 2017 Sep 1. Eur Urol. 2018. PMID: 28866255 Free PMC article.
BACKGROUND: Androgen receptor splice variant 7 (AR-V7) has been implicated in resistance to abiraterone and enzalutamide treatment in men with metastatic castration-resistant prostate cancer (mCRPC). Tissue- or cell-based in situ detection of AR-V7, however, has bee …
BACKGROUND: Androgen receptor splice variant 7 (AR-V7) has been implicated in resistance to abiraterone and enzalutamide treatment in men wi …
Prostate Cancer Screening in a New Era of Genetics.
Cheng HH, Pritchard CC, Montgomery B, Lin DW, Nelson PS. Cheng HH, et al. Among authors: nelson ps. Clin Genitourin Cancer. 2017 Dec;15(6):625-628. doi: 10.1016/j.clgc.2017.05.024. Epub 2017 May 31. Clin Genitourin Cancer. 2017. PMID: 28697982 Review.
Although clinically important, there is lack of specific guidance regarding management strategies for men at increased risk owing to germline mutation status or family history of aggressive prostate cancer. We review prostate cancer genetic risk factor …
Although clinically important, there is lack of specific guidance regarding management strategies for men at increased risk owing to germlin …
The Path of Most Resistance: Transdifferentiation Underlies Exceptional Nonresponses to Androgen Receptor Pathway Inhibition in Prostate Cancer.
Sinha S, Nelson PS. Sinha S, et al. Among authors: nelson ps. Cancer Discov. 2017 Jul;7(7):673-674. doi: 10.1158/2159-8290.CD-17-0481. Cancer Discov. 2017. PMID: 28684411
In this issue of Cancer Discovery, Zou and colleagues describe a mechanism involving cellular transdifferentiation that promotes exceptional resistance to antiandrogen therapy in prostate cancer. ...These findings have implications for developing a …
In this issue of Cancer Discovery, Zou and colleagues describe a mechanism involving cellular transdifferentiation that pr …
435 results